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IMPACT STATEMENT
Heart failure presents an increasing public health burden of
morbidity and mortality even as the mortality from coronary
artery disease and hypertension is decreasing. While effective
pharmacologic therapies have improved outcomes for mild-
moderate heart failure, the impact of newer therapies and
mechanical circulatory support for advanced heart failure has not
yet been realized. Implantable devices have been shown to be
safe and effective as bridges to cardiac transplantation, but
further work is needed to establish the role of mechanical support
for myocardial recovery and for long-term support. This confer-
ence was held to assess current mechanical support applications
and future trial designs for investigation affecting this public
health issue.
The participants concluded that important differences be-
tween devices and drugs may warrant novel study designs
characterized by innovation and flexibility. While the random-
ized clinical trial remains the most powerful tool for unambig-
uous comparison of interventions, variations may include timed
graduation from control to investigational therapies, assignment
influenced by patient risk or patient preferences and criteria for
an optional crossover to compassionate device use. A major
impact would result from a national outcomes database for
advanced heart failure that identifies high-risk populations with
*The recommendations set forth in this report are those of the conference
participants and do not necessarily reflect the official position of the American College
of Cardiology. The full text document will be published in the Journal of the American
College of Cardiology, and the executive summary will be published in Circulation, the
Journal of Heart and Lung Transplantation, and the Journal of Thoracic and Cardio-
vascular Surgery. This document is available on the World Wide Web site of the
American College of Cardiology (www.acc.org). Reprints of this document are
available for $5.00 each by calling 800-253-4636 (U.S. only) or by writing the
Resource Center, American College of Cardiology, 9111 Old Georgetown Road,
Bethesda, Maryland 20814.
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the greatest potential for benefit from newer therapies and thus
facilitates the design of devices and device trials. A separate
registry with industry of outcomes after device placement would
help to identify “breakthrough” device therapies and facilitate the
refinement and acceptance of this new technology. As represented
in this conference, progress in mechanical circulatory support will
be accelerated by the continued coordination of scientists, engi-
neers, industry, clinical investigators and regulatory and pay-
ment agencies in prospective partnership.
INTRODUCTION
Over the past five years, mechanical circulatory support
devices have evolved from the earlier investigational stages
to become standard therapy for bridging to transplantation,
in some cases extending beyond original indications. As the
first randomized controlled trial of mechanical circulatory
support, the Randomized Evaluation of Mechanical Assis-
tance in the Treatment of Congestive Heart Failure (RE-
MATCH) trial began in 1998 and has undergone regular
protocol modifications resulting from experiences gained
with the patient population and the devices themselves. In
1999, an expert review panel for the National Heart, Lung
and Blood Institute (NHLBI) recommended continued
support for the development of total artificial heart pro-
grams. Refinement of currently available left ventricular
(LV) devices continues steadily, and many new types of
support devices are in or approaching clinical trials. Ethical
and practical issues have emerged regarding the design and
funding of these future clinical trials. Challenges for optimal
application are being compounded as the separation be-
tween indications for recovery, bridge to transplantation and
permanent use is becoming less distinct.
As in the original conference on trial design for mechan-
ical circulatory support led by Pae in 1995, the goals of
investigators, governmental agencies and industry remain
the establishment of clinical trials that are “scientifically
sound, clinically meaningful and achievable in a finite time
frame at reasonable expense.” With the rapid increase in
experience with populations of advanced heart failure,
broader clinical application of available devices and the
promise of new technology for future support, members of
the steering group for the NHLBI, the Food and Drug
Administration (FDA), the American College of Cardiol-
ogy Committee on End-Stage Heart Failure and the Inter-
national Society for Heart and Lung Transplantation
sought broad representation from professional societies and
industry to address the issues involved in trial design for
mechanical circulatory support looking ahead from 2000.
The professional societies with significant interest in this
field were invited to co-sponsor this conference and to select
delegates to participate in the discussion and writing of the
draft document. The writing groups established the basis of
their conclusions for discussion and subsequent revision by
all participants during the conference at the Heart House in
Bethesda, Maryland, to which representatives of industry
were also invited. The published document represents the
consensus of the participants, as approved by the Steering
Committee, and does not imply formal acceptance by any of
the societies represented. New developments will render the
specifics of this document obsolete, but it is hoped that the
fundamental considerations established here will help to
guide trial design and clinical decisions for the near future.
EXECUTIVE SUMMARY
Present Status of Devices for Heart Failure
Current use of mechanical circulatory support devices is
dominated by the indications of post-cardiotomy shock and
bridging to cardiac transplantation. In the U.S., about 6,000
patients a year receive support devices after cardiac surgery,
with hospital survival of 20% to 40%. Sustained improve-
ment of native heart function after support also occurs in 5%
to 15% of transplant candidates, with greater frequency of
recovery in patients with fulminant myocarditis. Bridging to
cardiac transplantation occurs in 300 to 400 patients yearly
in the U.S., with an overall discharge rate of 50% to 70%
from device implantation through transplantation.
Limitations in our current conception of device indica-
tions need to be recognized. First, the need for biventricular
versus univentricular support is difficult to determine. Sec-
ond, the ultimate utility of a total artificial heart versus
ventricular assist device(s) (VAD) has not been established.
Third, the intended duration of mechanical support is a
moving target. The time and type of device utilization is
influenced by external factors such as the time to myocardial
recovery, donor organ availability, the potential of outpa-
tient therapy and the unpredictability of adverse events
associated with new technology. Thus, even within the field
of currently used devices, evolving indications mandate
flexible guidelines for utilization.
Development of Drugs and Surgical Devices
for Advanced Heart Failure
Observation provided the basis for early therapies of heart
failure, many of which have subsequently been abandoned.
A systematic approach to testing pharmacologic therapies in
heart failure has arisen only within the last 20 years. The
basis of evidence supporting the current medical therapy
with angiotensin-converting enzyme inhibitors and beta-
adrenergic receptor antagonists has arisen from double-
blind, randomized controlled trials in hundreds to thou-
sands of patients with mild to moderate heart failure.
Except for digoxin, oral inotropic agents have been shown
in controlled trials to increase mortality, despite sound
theoretical rationale. The template of the double-blind,
randomized control trial has emerged as the gold standard
for evaluating new pharmacologic therapies. It has not been
applied to urgent therapies such as diuretics for relief of
pulmonary edema and intravenous inotropic agents for
cardiogenic shock (CS), during which placebo therapies
might be regarded as unacceptable.
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Many surgical approaches have been introduced for heart
failure. The coronary artery surgery trial demonstrated
benefit in patients with reduced left ventricular ejection
fractions (LVEFs) but did not target patients with symp-
tomatic heart failure. Requiring five years to complete
enrollment, the trial of revascularization for acute CS
demonstrated benefit in patients ,75 years of age. Revas-
cularization, valve surgery and other remodeling techniques
are being employed for some patients with more severe
chronic heart failure (HF). The inability to provide compa-
rable placebo therapy, strong patient preferences regarding
invasive procedures, and the front-loaded risk of operative
procedures have complicated the evaluation of these new
approaches.
Fundamental differences between drugs and devices. As
therapies for heart failure advance beyond drugs into pro-
cedures and devices, fundamental differences emerge in the
evaluation of efficacy. By contrast with drug development,
progress with devices is more incremental, with experience
leading to progressive device modifications. The impact of
devices is more transparent, in part because the most
obvious risks are front-loaded compared with those from
new drugs. It is harder for the effects of devices to be masked
or mimicked by the natural history of heart failure. Practical
considerations relate to the higher order of magnitude of
expense per patient in a trial, which can be prohibitive for
companies without major revenue from previous products.
The clinically meaningful benefit, however, is projected to
be larger than the benefit of new drugs, such that estimated
sample sizes are in hundreds rather than thousands of
subjects. The experience and skill necessary to achieve
optimal outcomes restrict center participation in trials and
limit the generalizability of results. A crucial difference
between drugs and devices is the inability to blind patients
or physicians to therapy, a limitation with both ethical and
practical implications for clinical trials.
The sum of evidence guiding therapy with drugs is
dominated by evidence from large trials completed prior to
drug approval. Once it is approved, it is difficult to identify
use and attribute effects of any particular drug because of
variable prescription, adherence and combination with other
medications. For this reason, post-marketing surveillance
provides limited information regarding drugs for heart
failure, except for non-cardiovascular side effects. By con-
trast, the very complexity and undisguised impact of devices
render their use and outcomes easier to track, as long as
appropriate registries are maintained. The cumulative body
of evidence guiding the ultimate use of devices may be
drawn more from information gained after initial approval.
Target Populations and End Points
for Mechanical Circulatory Support
Target populations for mechanical circulatory support can
be defined by the expected natural history of heart failure.
Patients with CS have an in-hospital mortality of .50% but
also carry high risk for patient-related operative complica-
tions. Ambulatory patients without resting symptoms on
standard oral therapy often survive for two years or longer.
Despite various approaches to risk stratification, it remains
hard to specify an intermediate-risk population. For patients
receiving outpatient intravenous inotropic therapy, the six-
month mortality is currently in the range of 50%. However,
without objective indications for and restrictions on this
therapy, it may encroach on the population with less
advanced disease. Another target population might be
cardiac transplant patients with triple vessel coronary artery
disease (CAD) and decreased ejection fraction, with ,50%
one-year survival, but mechanical devices in the post-
transplant population may be complicated by previous
surgery and immunosuppression. The target population for
trials should be defined widely to include patients with the
best natural history compatible with the degree of certainty
that a given device will provide an improvement. This
would be greatly facilitated by a multicenter registry of
advanced heart failure. After approval, ongoing re-
evaluation of a successful device should reflect the observed
trend for downshifting risks, in which procedures with
proven benefit in a high-risk population become generalized
to patients with less risk of post-operative complications but
potentially less benefit.
End points for clinical trials will be chosen according to
the severity of disease in the population selected. For
patients with the most severe disease, early survival will be a
fundamental end point. A combination of early survival and
functional end points may be most appropriate for trials
allowing eventual device placement in patients randomized
to medical therapy. As the risk of death becomes imminent,
measurements of functional capacity, quality of life and
survival adjusted for patient preferences become increasingly
relevant. At all levels, measures of efficacy will need to be
supplemented by measures of cost-effectiveness. It should be
emphasized, however, that cost-effectiveness for a successful
device is likely to improve after approval, as experience is
gained and costs are decreased.
The Spectrum Including “Breakthrough” Devices
In the future, initial studies could identify a therapy with
such an obvious impact on survival that it would be
considered a “breakthrough” for a population with otherwise
high early mortality (Fig. 1). In retrospect, cardiac trans-
plantation was considered a breakthrough that has been
widely accepted without a controlled study. Most new
therapies do not enter the breakthrough realm during
preliminary testing but fall somewhere else along the spec-
trum before approval. Outside of breakthroughs, there may
be some therapies that are not yet approved but are
considered by experienced clinicians to be so effective that
waiting for a controlled trial would not be ethical. The best
way to bridge this gap to expedite approval from regulatory
agencies has not yet been determined for any of the
life-threatening diseases. The focus of this conference is not
on the approval process but on designing trials of devices for
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which there is reasonable doubt regarding efficacy. Even for
devices in the breakthrough realm for end-stage disease, the
design of trials would remain relevant for extension to those
populations with lesser severity of illness, in whom the
benefit of the device could not be assumed.
Trial Design for Mechanical Circulatory Support
All new devices are required by the Medical Device Amend-
ments Act to be “safe and effective,” as shown through
“well-controlled scientific studies” or “valid scientific evi-
dence.” Because mechanical circulatory support devices fall
into the highest of three risk categories, the sponsor must
conduct clinical trials before the FDA grants a pre-
marketing approval (PMA) decision. Multiple challenges
characterize the performance of these trials for mechanical
support devices. Because device innovation, exemplified by
left ventricular assist devices (LVADs), is incremental and
iterative, it is difficult to determine when a device should
come to clinical trial and which aspects of development
should be “frozen” while modification continues throughout
the investigational and post-marketing stages. There is little
precedent for trial design when a high severity of illness
limits the duration of observation and humanistic concerns
dictate consideration of alternate therapies outside protocol.
Other life-threatening illnesses, such as cancer and AIDS,
have led to consideration of research designs to minimize
ethical conflicts and shorten the PMA processes while
shifting more emphasis to rigorous post-marketing studies.
The randomized controlled trial (RCT) remains widely
regarded as the most powerful and sensitive tool for com-
paring therapeutic interventions and the most persuasive
force for the acceptance of new technology. Many of the
differences between drugs and devices, as detailed in the
preceding text, complicate the translation of RCTs from
pharmaceutical trials to trials of mechanical support devices.
Ethics of randomized controlled trials for mechanical
circulatory support. Special emphasis was placed by this
conference on consideration of the ethics of RCTs for
mechanical support devices. A fundamental tenet of the
ethical RCT is that equipoise exists for the treatment being
tested; it would thus not be ethical to do an RCT of a device
already determined from initial testing to be in the break-
through realm for the population being considered. Theo-
retical equipoise, in which available data and investigator
preference are exactly balanced, may in fact never be located
for the individual clinician. Clinical equipoise, in which
genuine debate and uncertainty exist among the clinical
community, is more feasible and relevant. Although it was
initially challenged for the REMATCH trial, the position
of equipoise was strengthened by the analysis of pilot data
from the pilot trial for REMATCH (PRE-MATCH), in
which no clear survival benefit from the LVAD could be
seen at three months.
After randomization has taken place, the patient and his
physician are aware of the selected therapy, unlike partici-
pation in the placebo arm of a double-blinded drug trial.
The combination of life-threatening disease and unblinded
therapy raises ethical issues beyond that of physician equi-
poise at the start of the trial. The visible impact of the device
may threaten maintenance of equipoise for investigators
following patients during the course of a trial. Responding
as individuals to unfiltered information, patients are less
likely to be in positions of equipoise even before random-
ization. Patients consenting to new trials are likely to be
already biased toward the procedure and thus may perceive
randomization to the control arm as a loss of hope, with
potentially deleterious impacts on individual outcomes.
Practical issues of randomized controlled trials for me-
chanical circulatory support. Patient preference for spe-
cific therapies perceived to be life-saving may limit enroll-
ment, particularly when a similar therapy is perceived to be
Figure 1. Line depicting the relationship between equipoise and efficacy of a new therapy, as perceived after initial clinical testing. It is possible that the
early experience could be so dramatic that both the scientific and regulatory community regard it as a “breakthrough” therapy that should be approved
without further investigation for the defined population. Initial experience could also demonstrate sufficient success that the scientific community is
convinced of efficacy, while the regulatory agencies require further information. This gap might be bridged by continued clinical investigation at limited
sites, with prospective definition of a non-randomized cohort for comparison. In the majority of cases, initial testing does not establish efficacy, and clinical
equipoise can be maintained for the performance of randomized controlled trials. It is anticipated that patient preference regarding new therapies will most
often lie to the right of clinical equipoise, complicating trials of therapies that cannot be blinded. The asymmetry of the line to the right of equipoise reflects
the enthusiasm necessary to drive any therapy through clinical evaluation.
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offered by other routes. From a methodologic aspect,
randomization does not eliminate evaluation bias when all
parties know the treatment received. Patient dissatisfaction
regarding treatment choice threatens compliance with
follow-up and increases the likelihood of off-protocol ther-
apy that could compromise the trial results, as was seen in
early trials of AZT for AIDS.
The cost of initiating a randomized trial for a new device
greatly exceeds that of continuing to report uncontrolled
experience. For this effort to be undertaken, the ultimate
value in terms of acceptance as an effective device must be
consistently endorsed. Financial impediments have pro-
foundly impaired the conduct of clinical trials of devices, for
which there have been substantial unreimbursed costs.
These disincentives to enrollment increase the duration and
overall cost of the study, delaying the time to potential
recovery of development costs. Government support for
reimbursement of routine Medicare treatment costs and
“conditional coverage” of treatment costs in recognized
scientifically-designed trials are strongly endorsed by this
conference.
Despite a number of obstacles, an RCT of classical design
is nearing completion to determine the impact of an
implantable mechanical circulatory support device as desti-
nation therapy compared with optimal medical therapy. If
the REMATCH trial proves a survival benefit for devices in
this population, similar devices may be tested against this
benchmark. Regardless of the outcome of this trial, both the
lessons learned during its conduct and the ultimate results
will have a profound influence on the design of future trials.
Modifications of the randomized controlled trial for
mechanical cardiac support. It should be recognized that
the gold standard methodology for evaluating the impact of
a treatment on outcome remains the randomized, double-
blinded, placebo-controlled trial. It should also be recog-
nized, however, that surgical interventions in advanced
illness may not appropriately lend themselves to all aspects,
such as blinding, of this methodological gold standard.
With increasing appreciation for the unique aspects of
mechanical circulatory support for advanced heart failure,
variations in the design of randomized trials merit consid-
eration.
The aspects of randomization and a control arm can be
retained in a non-blinded trial with an option to receive
active device therapy as “compassionate use” after the
achievement of a predefined time or intermediate end
points. (Because only the original cohorts would be com-
pared, this does not represent a true crossover design.) This
feature may encourage recruitment and retention, while
re-aligning incentives for the patient and physician to
continue full efforts after randomization to a control arm.
Models for randomized trials that allow some degree of
patient preference could improve recruitment and patient
satisfaction while providing more information on outcomes
for patients not desiring device therapy. The degree to
which patient preference should influence the choice of
therapy remains a major ethical issue for this and other
life-threatening conditions. From a more practical stand-
point, it is not clear to what extent the advantages of design
modifications would outweigh the increase in sample size
that would be required.
Comparison of non-randomized cohorts. In the absence
of a randomized control group, there are no large historical
groups that could be considered for comparison. Contem-
porary cohort studies offer better information than observa-
tional reports without comparison, but they are compro-
mised by a major bias in favor of new treatments. Data
provided by a cohort analysis of the bridge-to-transplant
experience indicated a major benefit from the device for that
indication. While this cohort data were often cited to
suggest that a randomized trial of therapy in non-transplant
candidates was not ethical, its relevance to this different
population was questioned when the small randomized pilot
trial indicated no major difference in early outcomes be-
tween the device and optimal medical therapy.
Alternatively, to generate prospective control groups,
cohorts could be defined by an obligatory control period
prior to enrollment that could provide short-to-
intermediate-term information, after which, however, sub-
jects entering surgery might be either better or worse than at
initial evaluation. Comparison of patients preferring surgery
to patients preferring medical therapy would require an
extensive adjustment for baseline factors influencing out-
come, not all of which can be identified. For non-
randomized cohorts, it is not possible to adjust for all of the
factors that lead to the provision of a therapy to one patient
and not another. A different approach to outcomes adjusted
for severity of illness is being investigated for therapy of
breast cancer, in which therapy is allocated only to the
patients at highest risk, whose outcome is then compared
with that projected from a less compromised population on
standard therapy, according to a mathematical model. This
technique and all of the regression models used to control
for cohort differences would require a deeper knowledge of
risk profiles and outcomes for advanced heart failure than
that which currently exists.
Vital Role of Registries
The absence of broad-based data and the magnitude of
mortality, morbidity and resource utilization argue strongly
for the creation of a registry of advanced heart failure. Such
a multicenter registry would advance both risk stratification
for outcome prediction and the development of a multivar-
iate regression model to help adjust for differences between
cohorts. Greater confidence in our ability to identify high-
risk populations would sharpen trial design and accelerate
recognition of devices in the breakthrough realm. Design of
RCTs would be streamlined by better selection of target
populations and better prediction of event rates.
There is now broad consensus that responsible progress in
the field of mechanical circulatory support requires the
establishment and maintenance of a mandatory registry that
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includes all implantable devices, both before and after
approval. It should be possible to require specific baseline
data collection on patients with mechanical assist devices
after device approval if that stipulation is formally linked to
the initial approval. By contrast to pharmaceutical therapies,
which are easier to study before approval and harder to track
afterward, mechanical circulatory support devices may, with
appropriate registry documentation, be supported by a
weight of evidence distributed differently between pre- and
post-approval experiences.
The Near Future
The lessons learned through the use of current technology
have led to formative strategies regarding the timing of
implantation, rehabilitative potential and discharge man-
agement in patients supported with circulatory assist de-
vices. However, limitations of systems requiring external
power sources connected through percutaneous drivelines
have led to the development of numerous systems that are as
completely implanted in the body as possible. This has
resulted in developments along two broad approaches. The
first is a refinement of implantable pulsatile systems, includ-
ing the Abiomed and Penn State/3M total artificial hearts,
the Thoratec IVAD, the Novacor II, the World Heart
Heartsaver VAD and the Arrow LionHeart VAD. The
majority of these systems utilize transcutaneous power
transmission and either an integral or component volume
compensatory mechanism. A second thrust utilizes a com-
pletely new concept of axial flow technology for chronic
support and includes the Nimbus/TCI HeartMate II, In-
tracorporeal Ventricular Assist System (IVAS), the Jarvik
2000 IVAS and the DeBakey/Micromed IVAS. These
systems also depend on transcutaneous power transmission
but eliminate the need for volume compensation. The
AB-180 Circulatory Support System, the HeartMate III
LVAD and the CorAide are devices based on centrifugal
principles. In many ways our limited understanding of the
impact of this latter group of devices may dictate newer
study design principles.
Although there are no specific standards for the pre-
clinical evaluation of newer mechanical circulatory support
systems, guidelines do exist. A Preliminary Draft Guidance
for Ventricular Assist Devices and Total Artificial Hearts
issued by the FDA in December 1987 needs to be updated.
The joint paper developed by the American Society for
Artificial Organs (ASAIO) and the Society of Thoracic
Surgeons (STS) addresses only reliability concerns for long-
term devices and does not address emerging technology for
which a comprehensive standard with criteria for pre-
clinical testing is still needed. The revision of these guide-
lines becomes even more important as distinctions between
short-, intermediate- and long-term support become in-
creasingly blurred during clinical application. An interdis-
ciplinary effort needs to address the development of a
comprehensive standard for the pre-clinical evaluation of
blood pumps, taking into account the uniqueness of each
system and its intended use, yet remaining sufficiently
flexible to incorporate new clinical experience.
As the field moves ahead, it has become clear that no one
trial design or set of standards will be ideal or appropriate
for all of these devices, populations and stages of develop-
ment. This document represents both consensus and con-
troversy from leading scientists, clinical investigators, rep-
resentatives of industry and regulatory agencies. One of the
most important achievements of this conference may be the
recognition that the pace of real progress in mechanical
circulatory support will be accelerated by ongoing collabo-
ration.
[END OF EXECUTIVE SUMMARY]
I. CURRENT STATUS OF MECHANICAL CARDIAC
SUPPORT
A variety of devices are available to patients depending on
the indications for support (1). In Table 1, the devices that
have been used in more than 100 patients in the U.S. are
listed, along with the chief characteristics that determine
present use. Currently, specific device use is governed by the
FDA.
Devices for circulatory support are currently used in three
broad categories: 1) acute CS with support ,1 month; 2)
more prolonged support from 30 days to .1 year; and 3)
permanent support as an alternative to transplantation (2).
The acute, short-term group includes patients who have
cardiac failure after cardiac operations, myocardial infarc-
tion (MI) shock or acute cardiomyopathy due to myocarditis
or other causes, with a potential likelihood of recovery. In
the intermediate or long-term group are those who are
suitable for transplantation but deteriorate before a heart
becomes available and require mechanical support prior to
transplantation. A small percentage of these patients with
chronic HF regain ventricular function and are able to have
the devices removed without requiring transplantation. The
third group of patients has irreversible cardiac failure that
might require circulatory support, but they are not good
candidates for cardiac transplantation. Therefore, if devices
are inserted, they must be considered permanent or “desti-
nation therapy” and are currently investigational.
The acute heart failure patients are still comprised pri-
marily of those requiring support after cardiac operations
and represent about 1.5% of the 400,000 patients who
undergo cardiac operations in the U.S. each year. Post-
cardiotomy patients may require support for a variety of
problems, often relating to the sequelae of perioperative MI,
valve disease or problems of myocardial preservation. Sev-
eral devices are available to support post-cardiotomy shock
patients. The simplest device is extracorporeal membrane
oxygenation (ECMO), a cardiopulmonary bypass system
with venoarterial cannulation placed either through the
femoral or intrathoracic vessels. These systems are limited
by their short-term usefulness of ,1 week and by problems
346 Stevenson and Kormos, et al. JACC Vol. 37, No. 1, 2001
Mechanical Cardiac Support 2000 January 2001:340–70
with bleeding and coagulation. The systems have been
improved recently by heparin coating of the circuits, which
may reduce the incidence of thromboembolism as well as
the bleeding caused by anticoagulation. However, these
systems do not always provide adequate LV decompression,
a primary determinant of recovery. Often the ECMO
system, the centrifugal or the Abiomed VADs are used as
systems for acute resuscitation to salvage severely ill patients,
who are subsequently determined to be transplant candi-
dates and are converted to a bridge to transplant device
(Thoratec, Cardiowest, Novacor and HeartMate), thus
creating a “bridge to a bridge.” Four centrifugal pumps are
currently available and provide the advantage of biventricu-
lar support, but they also present problems of anticoagula-
tion (3). Two VADs, the Abiomed (4) and the Thoratec
(5), offer the advantages of pulsatility, specially integrated
cannulas for a variety of cannulation options, and more
sophisticated control systems. The Thoratec VAD allows
for ambulation and management out of an ICU setting.
Currently, none of these systems allows for hospital dis-
charge of patients in the U.S. However, clinical trials with a
portable driver (Thoratec) are ongoing, and the driver is
approved for use in other countries.
Outcomes of post-cardiotomy support are similar regard-
less of the device employed (1) and relate primarily to age of
recipient, timing of insertion and degree of completed MI
(3,4). Survival rates range from 20% to 40% with compli-
cations of bleeding (25% to 45%), renal failure (20% to
30%), multiorgan failure (20% to 25%), thromboembolism
(4% to 20%), neurological deficit (5% to 20%) and infections
(35% to 60%), of which only 5% to 10% are actually device
related. A small group of patients in the post-cardiotomy
group undergo support for a period of time without recovery
of cardiac function and become candidates for cardiac
transplantation. With the Thoratec VAD, the only device
approved for both post-cardiotomy support and bridge to
transplantation, there were 34 patients who underwent
bridge to transplantation after a recent cardiac operation.
Seventy-one percent were transplanted and 53% were actu-
ally discharged from the hospital. By comparison, of 536
patients primarily implanted with Thoratec VADs as a
bridge to transplantation, 328 or 61% were transplanted,
and of those, 284 survived (87% of those transplanted), with
an overall survival rate of 53%. However, it is important to
note that in the post-cardiotomy group, only 75% of those
transplanted survived, while in the primary VAD bridge-
to-transplant group, 87% of those transplanted survived.
Post-MI support represents about 10% of all patients
treated with VADs. This application has not been widely
employed, because of the wide range of co-morbidities
encountered by such patients, many of whom succumb
before surgery can be performed. Of those implanted with
VADs after acute MI with CS, the majority have been
considered unsuitable for coronary revascularization. How-
ever, the VAD in this population, either post-cardiotomy or
after failed medical management, may serve either as a
bridge to transplant or bridge to recovery, providing an
emerging potential application. Recent experiences when
LVADs were implanted within 14 days after acute MI have
shown a survival rate of 74% to transplantation or explan-
tation (6). This experience suggests that VAD implantation
for post-MI CS may be able to reduce the mortality of 65%
to 80% currently associated with medical management.
Acute dilated cardiomyopathy has a variety of etiologies,
Table 1. Current Status of Mechanical Cardiac Support Devices
Types of
Devices ECMO Centrifugal Abiomed Thoratec Novacor HeartMate Cardiowest
FDA approved
indications
N/A N/A Post-cardiotomy
recovery
Post-cardiotomy
recovery and
bridge
Bridge Bridge Bridge*
Position External External External External Internal Internal Internal
Ventricular
support
Cardiopulmonary Left, right or
both
Left, right or
both
Left, right or
both
Left only Left only Left and
right
Patient size Small-large Small-large Small-large Medium-large Large Large Large
Average
duration
Short Short Intermediate Intermediate to
long
Long Long Long
Power source Electric Electric Pneumatic Pneumatic Electric Electric or pneumatic Pneumatic
Cannulation
site
Arterial and venous Arterial, atrial or
ventricular
Arterial, atrial or
ventricular
Arterial, atrial or
ventricular
Ventricular Ventricular N/A
Native
ventricle
Remains Remains Remains Remains Remains Remains Removed
Anti-
coagulation
Yes Yes Yes Yes Yes No Yes
Patient
ambulation
No No Yes, restricted Yes Yes Yes Yes
Wearable No No No No Yes Yes No
Patient
discharge
No No No No Yes Yes-electric,
yes-pneumatic*
No
Device cost $ $ $$ $$ to $$$$ $$$$ $$$$ N/A
*Investigational device exemption (IDE). ECMO 5 extracorporeal membrane oxygenation; FDA 5 Food and Drug Administration.
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the most common of which is myocarditis (7). This has
been an indication for LVAD implantation in about 15% of
all patients on VADs. The outcomes are quite variable, but
the potential for recovery is increased in younger patients,
patients who have had shorter periods of heart failure and
patients who have improved more rapidly after LVAD
implantation (8). Intermediate or long-term device support
(30 days to .1 year) has been employed largely for candi-
dates for cardiac transplantation whose condition deterio-
rates before hearts become available. Of approximately
2,400 cardiac transplants performed in the U.S. in 1997,
15% of those patients required circulatory support devices to
be bridged to transplantation. The types of devices used to
bridge patients include extracorporeal VADs, implantable
wearable LVADs and implantable biventricular replacement
devices. The most important evolution in this group of
patients has been the ability to discharge them from the
hospital with implantable wearable LVADs. However,
these LVADs do not provide for right ventricular (RV)
support. If severe right heart failure occurs, another device
must be implanted for the RV. Consequently, patients with
severe concomitant RV failure have usually been implanted
with extracorporeal VADs or implantable biventricular re-
placement devices. Approximately 10% to 15% of all pa-
tients implanted with wearable VADs have required right
heart support with another device.
Of the more than 3,000 patients who have been im-
planted with circulatory support devices as a bridge to
transplantation, approximately 60% to 70% actually received
a transplant. Of those who received a transplant, 85% to
90% survived to be discharged from the hospital (9–11).
Among those implanted as a bridge to transplantation,
approximately 5% recovered ventricular function and sur-
vived without cardiac transplantation. Approximately 25%
of patients from one series of more than 100 patients
implanted with VADs for bridge to transplantation recov-
ered ventricular function, and of those survivors, 14 retained
good cardiac function while the others later died or required
cardiac transplantation (8).
During the last year, at least 50% of patients receiving
implantable wearable LVADs have been able to be dis-
charged from the hospital, and patients have been supported
from periods of a few weeks to .4 years. Although patients
discharged from the hospital may require readmission for
problems of infection, anticoagulation or bleeding, the cost
of caring for these patients has been significantly reduced by
the out-of-hospital option. Currently, that option is avail-
able only with the implantable wearable LVADs and is not
available with the extracorporeal LVADs or the implantable
biventricular replacement devices. However, this option has
potentially important economic implications.
Complications occurring during bridge to transplantation
are well documented in individual series, but unfortunately
a reliable common registry is not currently available to
determine outcomes. From individual series, it is reported
that bleeding requiring reoperation occurs in 5% to 30%,
infections occur in 40%, and device-related infections occur
in only 5% to 30%. Thromboembolism has been reported in
5% to 25% of patients, with a stroke rate of 2.7% to 25%.
Elevated panel reactive antibodies (PRA) may complicate
the LVAD bridge to transplantation. These are presumed to
be due to anti-HLA antibodies induced by blood products,
cross-reactive antibodies to the device itself or antiphospho-
lipid antibodies due to exposure to fibrin glue (topical
bovine thrombin) or perioperative blood transfusions. The
consequent elevation of PRAs cause “positive” donor-
specific crossmatches that may delay transplantation. In one
large series (12) with the TCI HeartMate device, PRA
elevation to greater than 10% occurred in 66% of patients
post-LVAD but persisted in only 22% at the time of
transplantation. However, several patients required immu-
nosuppressive therapy and plasmapheresis to reduce the
PRA.
The final group of patients, who are not yet well defined,
are patients who have apparently irreversible cardiac failure
but are not good candidates for cardiac transplantation.
Enrollment is almost completed in the randomized, con-
trolled REMATCH trial, in which the TCI HeartMate
vented electric LVAD is compared with optimal medical
therapy in patients who are not candidates for cardiac
transplantation (13). The FDA has recently given permis-
sion for Novacor to begin a similar study of the permanent
implantation as “destination therapy” for patients with
severe cardiac failure who are not candidates for cardiac
transplantation. Unlike the REMATCH trial, the Novacor
study will not include a randomized control group. The
obvious impediments to the success of such long-term
device therapy are the risks of infection related to external-
ized energy sources, the threat of thromboembolic events
and mechanical failure. Although we do not have data from
the current studies to address these questions, it is apparent
that the long-term result will depend on solving these
problems. If these trials can demonstrate efficacy, it will be
appropriate to consider this therapy for similar patients
among the 50,000 to 100,000 patients in the U.S. who have
been estimated to potentially benefit from this technology
(14).
II. EVOLUTION OF THERAPIES FOR HEART FAILURE
A. Medical Therapies for Heart Failure
The evolution of therapy for heart failure presently includes
many strategies never tested by properly controlled clinical
trials (Table 2). Many treatments have been abandoned
without formal testing after unrewarding anecdotal experi-
ence. Over two millennia ago, treatment for what was once
termed “dropsy” was aimed at restoring a balance of funda-
mental elements and complementary humors (15,16). A
historical overview of more modern therapies (17) reveals
that in 1683, Thomas Sydenham recommended bleeding,
purges, blistering, garlic and wine. A century later, William
Withering provided a precise description of the benefits of
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foxglove in the Shropshire maid’s cure for dropsy. Catharsis
and venesection continued through the nineteenth century,
with amyl nitrate, mercurial diuretics and digitalis glycosides
becoming available in the early part of the twentieth century.
While the laboratory experience was developing that
allowed human cardiac transplantation to proceed, medical
therapy for heart failure included only digitalis, thiazide
diuretics (introduced in 1962) and furosemide (introduced
in 1965). Controlled trials of withdrawing or administering
digoxin did not take place until 1993 (18,19) and 1997 (20),
and there were no trials of diuretics except as substudies of
two trials testing other drugs (21,22). The quest to establish
a basis of evidence from which to prescribe effective thera-
pies for specified populations has been relatively recent (23).
The concept of vasodilators for heart failure was introduced
by the acute use of nitroprusside in 1974, followed by
hydralazine in 1977. The first large randomized clinical trial
in heart failure with mortality end points was not completed
until 1986 (24), demonstrating improved survival with the
hydralazine-isosorbide dinitrate combination. With the re-
lease of captopril in 1980 and enalapril in 1984, multiple
large, randomized, placebo-controlled trials established
angiotensin-converting enzyme inhibitors as the corner-
stone of therapy, with extensive unforeseen benefits for this
drug class occurring beyond that expected only from vaso-
dilation (25–28).
Trials have also demonstrated the lack of sustained
clinical benefit from many therapies with sound theoretical
rationale. Although acute hemodynamic improvements in
heart failure patients were readily demonstrated with dopa-
mine in 1972 and dobutamine in 1974, inotropic agents
have not been associated with sustained hemodynamic
benefit or mortality reduction during chronic therapy. In
fact, mortality is increased in these patients, as suggested by
early experiences and confirmed in larger trials (29). Al-
though excess myocyte calcium concentrations have been
implicated in progression and death, calcium channel block-
ers have worsened heart failure and survival in retrospective
analyses and prospective trials. Many anti-arrhythmic
agents that suppress ventricular arrhythmias were shown in
large trials to increase death in patients with heart failure.
Amiodarone, the only currently available anti-arrhythmic
agent that does not increase mortality in heart failure, may
in fact have more benefit for heart failure end points than for
sudden death. Beta-adrenergic blocking agents worsen he-
modynamics initially but, when tolerated, lead eventually to
improved hemodynamics and survival in recent large trials
of mild-to-moderate heart failure.
Reviewing the history of introduction, adoption and, in
some cases, abandonment of therapies for heart failure,
reveals the contribution of large controlled trials in defining the
additive impact of our interventions. In the process of estab-
lishing a basis of evidence to guide current medical therapy for
heart failure, a template has been created for the rigorous
testing of medications that can be administered in parallel with
placebo therapy. End points of survival, clinical status, cardio-
vascular function and cost-effectiveness can be evaluated using
this template without either patient or physician knowing who
has received the new therapy being tested.
However, the randomized placebo-controlled trials have,
in general, not included patients desperate for relief from
severe heart failure symptoms or hoping to be rescued from
imminent death. For example, the rapid impact of intrave-
nous diuretics in treating dyspnea from pulmonary edema in
heart failure, and the rapid benefit of inotropic therapy to
improve perfusion acutely in CS have not been put to the
test of placebo-controlled, randomized trials. The immedi-
ate cause-effect response typically observed renders a phy-
sician unlikely to substitute placebo therapy in these situa-
tions. Even in a less compromised group of hospitalized
patients, placebo-controlled trials have either excluded pa-
tients with urgent indications for intravenous therapy or
Table 2. Development of Therapies for Advanced Heart Failure
Pharmacologic Therapies
Herbal remedies (cathartics, purgatives, natural diuretics, foxglove)
Pharmaceutical compounds
c **Digitalis glycosides
c *Diuretics
c *Nitrovasodilators (**for combination)
c Hydralazine (**for combination)
c Neg**: Flosequinan
c Neg**: Epoprostenol
c **Angiotensin-converting enzyme inhibitors
c **Angiotensin receptor blockers
c **Aldosterone antagonists
c Neg**: Catecholamine-related oral inotropic agents
c Neg**: Phosphodiesterase-related oral inotropic agents
c Neg**: Calcium channel blocking agents
c **Beta-adrenergic receptor antagonists
Lifestyle Interventions
c Sodium restriction
c Alcohol restriction
c *Exercise training
Device Therapies
c Southey tubes to drain peripheral edema
c (*)Implantable cardioverter defibrillators
c A-V interval pacing
c (*)Biventricular pacing
Surgical Therapies
c Thyroidectomy
c Pericardiectomy
c Valvular heart surgery
c *Coronary revascularization
c Cardiac remodeling
c Aneurysmorrhaphy/aneurysmectomy
c (*)Infarct reduction
c Ventricular reduction surgery
c Cardiac transplantation
c Orthotopic
c Heterotopic
c Ventricular assist devices
c Post-cardiotomy
c Bridge to recovery from cardiomyopathy
c Bridge to transplant
c (*)Destination therapy
*Limited trial evidence; **substantial trial evidence; Neg** 5 substantial evidence of
harm or lack of benefit; (*)Trial in progress. It should be noted that harm or lack of
benefit can often be identified without controlled trials.
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limited placebo therapy to a short period with early cross-
over to active treatment.
B. Surgical Therapies for Heart Failure
Early surgical procedures for heart failure included thyroid-
ectomy, pericardiectomy and valve replacement. Subsequent
procedures, such as intra-aortic balloon counterpulsation for
CS (30), proposed in 1961, and LV aneurysmectomy
introduced for chronic HF in 1962 (31), were more system-
ically studied and reported but without specific control
groups against which to compare benefit. As soon as
orthotopic cardiac transplantation was performed in hu-
mans, it was tried in many centers with poor initial results.
In large part through the perseverance of the Stanford team,
outcomes steadily improved. Approval by Medicare of heart
transplant as standard therapy was based on careful descrip-
tion of outcomes for a cohort of patients assumed to have
over 50% six-month mortality without transplantation (es-
timates based on early waiting list deaths, but not on any
control groups). Increasing waiting times for transplantation
have led to expanding use of mechanical circulatory support
as bridging devices for cardiac transplantation. Comparisons
with patient cohorts without bridging devices suggested
better survival to transplantation and discharge, but no
randomized trials were done before the widespread accep-
tance of bridging strategies.
With a limited supply of donor hearts, research continued
into other surgical options for heart failure. Coronary
revascularization and valvular heart surgery, once thought to
be contraindicated in the presence of a low ejection fraction,
were extended into the heart failure population, where their
roles are not yet defined. A variety of cardiac remodeling
procedures (aneurysmorrhaphy/aneurysmectomy, infarct ex-
clusion, application of cardiac restraining and ventricular
splinting devices) have recently been introduced and re-
ported in small numbers. More systematic evaluations have
been recommended (31). In fact, there are developing plans
for a national randomized trial in ischemic heart failure to
compare medical therapy with surgical therapy, with further
randomization of the surgical arm with or without ventric-
ular reconstruction.
Despite the obstacles, large randomized clinical trials
have been performed with surgical therapies of advanced
cardiac disease. Three landmark trials of coronary artery
bypass surgery clarified its role in ameliorating morbidity
and mortality from coronary heart disease (32–34). The
smaller analyses of patients with three-vessel disease with
decreased LVEF demonstrated particular benefit but in-
cluded few patients with typical heart failure. With enthu-
siasm generated by uncontrolled experiences of cardiomyo-
plasty, the Cardiomyoplasty-Skeletal Muscle Assist
Randomized Trial (C-SMART) was an ambitious trial (35)
that included a non-blinded, control arm of patients with-
out cardiomyoplasty. Due to early problems with patient
recruitment and withdrawal to receive active therapy, the
protocol was changed to allow crossover to active treatment
after one year. After recruitment of only 100 patients over
five years because of ongoing problems with both patient
recruitment and reimbursement, the trial was terminated,
despite a trend for improved outcomes in the surgical group.
Revascularization is commonly employed as standard
therapy for CS due to an acute ischemic event. The Should
We Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock? (SHOCK) trial (36) of revasculariza-
tion for acute coronary syndromes causing CS was com-
pleted in 302 patients only after five years. Survival benefit
from revascularization was not apparent at one month but
shown by the six-month evaluation for patients under 75
years. At the same time, the Swiss Multicenter Angioplasty
for Shock Trial was terminated because of inadequate
enrollment (37).
The ongoing REMATCH trial (13) faces the double
challenge posed by both a surgical trial and study of a more
compromised heart failure population than was ever en-
rolled in a controlled trial. Candidate criteria were originally
designed to include patients with an expected 25% two-year
survival. Considering previous information from cohort
experiences suggesting a large benefit from “bridging” in
transplant candidates, concern was raised that this trial was
unethical because it denied patients a life-saving therapy. In
fact, the 21-patient pilot trial prior to REMATCH dem-
onstrated a three-month mortality of almost 30% without
apparent difference between the medical and surgical arms.
Attempting to find a population with intermediate risk, the
inclusion criteria for REMATCH were subsequently ex-
panded to require 60 rather than 90 days of severe symp-
toms and either dependence on intravenous inotropic agents
or a peak oxygen consumption ,14 ml/kg/min, compared
with the previous limit of 12 ml/kg/min. Enrollment in the
trial has been limited by issues of reimbursement for the
surgical procedures, difficulty in regional recruitment at
designated centers and reluctance of patients and families as
well as physicians to accept randomization in the setting of
a life-threatening illness for which a new therapy might be
life-saving. Still, it is anticipated that the completion of this
trial in 2001 will provide new benchmarks for both the
medical and device arms of future trials.
C. Downshifting of Risk for New Surgical Therapies
The recognized success of new surgical procedures for
advanced disease may be followed in some cases by a cycle
of improving results and expanding population definition.
The evolution of such therapy contrasts with the develop-
ment of pharmacologic and exercise interventions, which
have usually been initiated in patients with mild disease,
validated in trials of moderate disease and ultimately ex-
tended to patients with severe disease who would have been
excluded from the landmark trials (38). Surgical therapies
for heart failure carry front-loaded risk that is easier to
absorb for patients expecting high early mortality. As
survival and improved function are realized by these desper-
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ate patients, the procedure is then sought by patients at
earlier stages of the disease. These patients are more likely
than the initial subjects to obtain good results from the
procedure. With the downshifting of risk, however, the
actual benefit, calculated as the difference between outcome
with the procedure and outcome without the procedure,
may become less significant. An appropriate example of
“downshifting” the risk is the evolution of cardiac transplan-
tation (39–41). Candidates were originally expected to have
“less than six months to live,” at which time survival with
transplantation was 60% to 70% at one year. The current
one-year survival rate after heart transplant is 80% to 85%,
with a 10-year survival rate of about 50%. For ambulatory
heart failure patients not requiring intravenous inotropic
agents, the survival without transplantation has also im-
proved to 60% to 70% without death or urgent transplan-
tation at one year in many studies, leaving a smaller margin
of early benefit. The positive impact of heart transplant
remains striking, however, for patients in critical status or
dependent on inotropic infusion. After initial experiences,
risk can shift up as well, as has happened for candidates
developing organ failure while awaiting transplantation,
such that procedures may be extended to patients who are
more severely ill than their predecessors. As new surgical
therapies for heart failure are introduced and accepted into
broadening populations, it remains crucial to monitor the
target populations and ensure that the benefits expected
from earlier experience are being derived.
III. TARGET POPULATIONS AND END POINTS
FOR MECHANICAL CIRCULATORY SUPPORT
A. Indications for Device Support
The appropriate population for a trial of mechanical circu-
latory support is comprised of the patients whose current
quality of life and prognosis are measurably worse than
expected outcomes for the device being tested. The popu-
lation should be defined as broadly as possible to maximize
generalization of the results. Although the specific entry
criteria will vary for each device and indication, there are
general categories of patients who can be considered along a
scale of disease severity (Table 3). As the severity of disease
increases, there is greater certainty regarding imminent
death, and less certainty is required regarding the device
performance and patient outcome after device implantation.
In general, however, increasing disease severity also in-
creases the risk of adverse outcomes attributable more to the
patient than to the device. At lesser grades of severity, when
death is not imminent, details regarding the expected
function and quality of life with mechanical circulatory
support become more critical. In one study, a majority of
patients anticipating continued heart failure symptoms at
rest expressed willingness to trade .50% of their remaining
time, or take .50% risk of death, for a chance to return to
more normal function (42).
1. Cardiogenic Shock
a. CRITICAL LOW OUTPUT STATE FROM EXACERBATION OF
CHRONIC HEART FAILURE. Most of the current experience
with mechanical support as bridging to transplantation
derives from the population of patients with chronic HF
that decompensates to a critically low output state threat-
ening tissue perfusion and organ viability. In the absence of
reversible factors, this state usually leads to death before
hospital discharge. When transplantation, and thus bridging
to transplantation, is not an option or when current bridging
techniques are not applicable, this population could be
considered for trials of newer support systems. Early iden-
tification of such patients would be desirable for these trials,
but it is confounded by difficulty in distinguishing revers-
ibility of organ system dysfunction and by the rapidity of
clinical progression. One study evaluated the ability of the
Acute Physiology and Chronic Health Evaluation II
(APACHE II) scoring system to determine optimum tim-
ing of VAD implantation in patients with lung rales, S3,
peripheral edema, ejection fraction ,30%, systolic blood
pressure ,80 mm Hg, progressive prerenal azotemia, al-
tered level of consciousness, gastrointestinal ischemia or
congestion or persistent but reversible pulmonary hyperten-
sion (43). By the end of the follow-up period, the VAD
patients had survived longer (560 vs. 256 days). Kaplan-
Meier analysis of non-VAD patients at low (#10), medium
(11–20) and high (.20) baseline APACHE II scores
revealed a decreasing survival with increasing APACHE II
scores. Similar outcomes were seen in VAD-treated pa-
tients. Patients with low APACHE II scores had similar
outcome regardless of whether or not they received VAD
support. However, when VAD and non-VAD patients with
medium APACHE II scores were compared, VAD-treated
patients had better survival, which was confirmed in a model
Table 3. Anticipated Survival According to Severity of
Advanced Heart Failure
Severity of Heart Failure
>50% Mortality
Expected
Cardiogenic shock In-hospital
Chronic heart failure with exacerbation
into critical low output state
In-hospital
Acute myocardial infarction In-hospital
Post-cardiotomy shock In-hospital
Chronic heart failure, dependent on
intravenous inotropic therapy
3–6 months
Chronic heart failure, class IV symptoms
on oral therapy
12–24 months
Refractory symptoms at rest or
minimal exertion
#12 months
Risk factors such as decreasing sodium,
increasing creatinine and/or blood
urea nitrogen
Stabilization as class III $24 months
Heart failure, refractory ventricular
arrhythmias
Variable, not estimated
Chronic severe post-transplant graft
dysfunction with allograft
vasculopathy
#12 months
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after controlling for baseline APACHE II scores. Although
this study concluded that the severity of illness measured by
APACHE II might be used to time insertion of devices for
bridging to transplant, it might also be used to identify
patients for urgent destination therapy. However, use of the
APACHE II score to predict short-term mortality in
patients with primary cardiovascular disease is limited, and
it is complicated by variances in interpretation of the scoring
system and errors in data capture (44). The use of a
modified APACHE II scoring system may improve the
accuracy and reproducibility of these methods (45). Exten-
sive prospective evaluations of the APACHE II system (or
a modification) are needed to further define the role of this
method of risk stratification of potential candidates for
mechanical support.
The frequency of CS complicating HF in transplant
candidates is difficult to estimate from the 15% of recipients
of “bridges” to transplantation, as the increased recognition
of the benefits of mechanical support have broadened the
application to patients with impending or anticipated cir-
culatory failure. In addition, this population also includes
patients bridged for more common causes of CS, such as MI
and post-cardiotomy failure.
b. CARDIOGENIC SHOCK AFTER ACUTE MYOCARDIAL IN-
FARCTION. It is estimated that 1.1 million patients suffer an
acute MI in the U.S. each year. Of these, approximately
one third die prior to presentation (46). In the large multi-
center Global Utilization of Streptokinase and Tissue-
Plasminogen Activator for Occluded Coronary Arteries
(GUSTO) trial, CS occurred in 7.2% of patients, but it
accounted for 58% of all deaths in the entire trial (47). The
estimated yearly incidence in the U.S. is 50,000 in the
hospital with post-infarction CS. In the SHOCK registry,
in-hospital mortality was approximately 60% in patients
with post-MI CS (48). Of the patients developing shock, it
was present initially in 10.6% and developed after admission
in the remaining 89.4%, usually within 48 h (49). In one
sub-study of GUSTO a prognostic algorithm predicted
with high accuracy the 30-day mortality in patients with CS
complicating an acute MI. Increased age was the strongest
demographic variable predicting 30-day mortality, and
shock at presentation had better outcome than shock
presenting later. Clinical predictors focused on findings of
peripheral hypoperfusion such as an altered sensorium, cold
and clammy skin and oliguria. Significant hemodynamic
predictors were a cardiac output ,1.5 L/min or a pulmo-
nary arterial wedge pressure .20 mm Hg. A serious
limitation of this prognostic algorithm is the lack of con-
sideration of revascularization, found in another GUSTO
substudy to reduce the 30-day mortality rate and in the
SHOCK trial to reduce six-month mortality (36). Based on
these data, a patient with CS after MI, especially if not a
candidate for revascularization, could be a candidate for
long-term mechanical support.
c. POST-CARDIOTOMY SHOCK. Post-cardiotomy shock is
described in approximately 1.5% of the 400,000 patients
undergoing cardiac operations each year in the U.S. As
discussed above, survival to discharge is in the range of 20%
to 40% (1–6). In the minority of patients who proceeded
through bridging devices to transplantation, the overall
survival rate to discharge was 40% to 60%. Patients who are
not candidates for transplantation could be considered for
trials of permanent mechanical support, but it should be
recognized that the factors rendering them ineligible for
transplantation would also affect outcome on devices. The
post-surgical state may also predispose to worse outcome
because the results of mechanical bridging to transplant
have been slightly less favorable in this population than in
primary bridging experiences.
2. Heart failure dependent on intravenous inotropic
support. The population of patients requiring intravenous
inotropic support is increasingly being considered as a
potential candidate group for newer heart failure therapies,
particularly those that carry significant risk. This population
definition is less precise, however, than others based on
immediately measurable parameters. Many patients hospi-
talized for heart failure exacerbations receive brief courses of
intravenous inotropic therapy to facilitate diuresis or rede-
sign an effective oral regimen, following which the inotropic
therapy is discontinued. Persistent efforts to achieve fluid
balance, the substitution or combination of different vaso-
dilators to avoid symptomatic hypotension and severe renal
dysfunction, and enrollment in heart failure management
programs frequently allow patients previously on intrave-
nous infusions to maintain a reasonable quality of life on
oral regimens (50).
Specific criteria for determining the ongoing need for
intravenous inotropic therapy have not been established,
despite numerous reports of chronic and intermittent intra-
venous inotropic therapy for ambulatory patients with heart
failure. The classification of disease severity is ambiguous
because patients on inotropic infusions may initially be
reclassified to the clinical level of class III symptoms, while
deterioration after discontinuation may take over 24 h to
become apparent. Definitions of “failed weaning attempts”
have been proposed (14), but identification of “symptomatic
hypotension” and “worsening renal dysfunction” remains
subjective. Despite the lack of uniform criteria for intrave-
nous inotropic support, the prognosis for patients receiving
either chronic or intermittent inotropic infusions outside
the hospital is remarkably consistent. This may reflect a
greater homogeneity of the population than recognized
and/or a dominant adverse effect of the infusions them-
selves. The mortality reported in representative series gen-
erally ranges between 30% and 50% by six months.
Among patients listed for transplantation as Status II in
the multicenter pre-transplant database, intravenous ino-
tropic infusions were being administered at the time of
listing in approximately 10% of the patients, of whom over
90% had died or deteriorated to Status I by the end of one
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year (51). In the pilot trial before REMATCH, 80% of the
patients were on inotropic infusions at the time of random-
ization, and 53% of the patients in the medical arm were
receiving inotropic infusions after hospital discharge (52).
Mortality in the medical treatment arm of the pilot experi-
ence for the REMATCH trial was 30% at three months,
consistent with the reported experiences on inotropic ther-
apy. There are not yet sufficient data regarding quality of life
to compare chronic intravenous inotropic therapy, which
requires maintenance of an indwelling catheter and infu-
sions, with LVADs, which require other equipment. Re-
gardless of the difficulties of establishing true dependence
on intravenous inotropic therapy, patients in this group
would appear to be reasonable candidates for consideration
of mechanical support devices, with which intermediate
outcomes are expected to be comparable or better.
3. Outpatients with symptomatic heart failure—who is at
intermediate risk? It is relatively easy to identify critically
ill patients not likely to survive until hospital discharge. For
this population, patient-associated factors related to infec-
tion, renal failure, hepatic failure and malnutrition may play
a greater role than device characteristics in post-operative
survival. It is also relatively easy to find patients with good
functional capacity and mild symptoms of heart failure who
are likely to survive at least two years. This population adds
relatively little patient-related risk to a new procedure but
does not offer large opportunity for measurable improve-
ment in outcome. Defining a population with intermediate
risk and mortality remains a major challenge.
Most of the information regarding outcomes in heart
failure derives from multicenter heart failure trials, domi-
nated by mild-to-moderate heart failure and one-year mor-
tality of ,20%. Even the trial populations intended to
include advanced class IIIb and class IV generally have
actual one-year mortality of ,30%, suggesting less severe
disease. Various biochemical, structural and functional char-
acteristics have been identified singly and in composite
scores that predict mortality in these populations but are
more uniformly abnormal among patients who would be
considered for mechanical support. Among two series of
patients with class III and class IV heart failure referred for
transplantation—representing a total of almost 1,000 pa-
tients—the combined end point of death and urgent trans-
plantation occurred in approximately 50% of the patients by
two years (53,54). A multivariate model including contin-
uous variables of heart rate, LVEF, mean blood pressure,
presence of intraventricular conduction delay, peak oxygen
consumption and serum sodium identified 19% of the
population with a one-year survival of 30% to 40% without
urgent transplantation (53). The other study indicated that
patients referred with class IV symptoms could be divided
approximately in half by serum sodium or LV dimension,
with a ,50% one-year survival for either a serum sodium of
,134 mEq/L or an LV diastolic dimension .75 mm (54).
From a multicenter study of 967 patients listed as Status II
for transplantation, class IV symptoms, higher creatinine,
higher pulmonary capillary wedge pressure, diagnosis of
ischemic heart disease and inotropic therapy at listing
predicted worse outcomes (51). Even among patients await-
ing transplantation, however, outcomes were relatively good
for patients having a non-urgent status listing, with only
30% dying or deteriorating to an urgent status within the
next year—most deaths occurring suddenly. The previous
risk predictions will be compromised in future applications
by broader use of implantable defibrillators.
Among patients out of the hospital on oral therapy, the
major distinctions are made on a clinical basis. Many
patients referred with class IV symptoms can regain stabil-
ity—some immediately, some after a prolonged period of
closely monitored adjustment of the medical regimen. From
a practical standpoint, many patients exhibit a dynamic state
that fluctuates over months, with exacerbations related to
dietary indiscretion, seasonal viral infections and other
exogenous factors. For ambulatory patients with heart
failure, a large component of the decision to receive inves-
tigational therapy, either medical or surgical, is the degree to
which the current clinical status is unacceptable. Patients
able to regain and maintain freedom from congestion during
close follow-up have a two-year survival of almost 80%
despite an initial admission with class IV symptoms (55).
Patient preference for quality of life versus survival shows
remarkable variation at every level of disease severity (42).
For an individual patient with severe heart failure being
evaluated for heart transplantation, certain pre-transplant
risk factors may make transplantation a relatively high-risk
option (56). Although transplantation may be offered to
such a patient despite this increased risk, an alternative
mode of therapy may be mechanical assistance. In addition,
an individual patient may decline transplantation because of
social, psychological or religious reasons. Although trans-
plantation may be indicated by medical standards in such
patients, mechanical assistance may also offer improved
quality of live and life span. It is not clear whether eligible
patients refusing transplantation should be excluded from
clinical studies of devices.
4. Uncontrollable ventricular arrhythmias. Approxi-
mately half of the deaths from heart failure occur suddenly
(57). Unexpected cardiac death is usually due to tachyar-
rhythmias, but it may result from bradyarrhythmias or
electromechanical dissociation in 10% of the general series,
more often as the end stages of cardiac disease are reached.
The implantable cardioverter-defibrillator is of limited effi-
cacy in the therapy of rapidly recurrent or incessant arrhyth-
mias because of limited battery life, high defibrillation
thresholds in the advanced cardiomyopathic ventricle, and
the downward spiral of hemodynamic instability. In addi-
tion, the quality of life can become unbearable under the
shadow of frequent defibrillations without anesthesia.
Therapy with amiodarone or combination of other anti-
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arrhythmic agents may reduce the number of device dis-
charges to a tolerable frequency. Recurrent tachyarrhyth-
mias from an identifiable focus may be amenable to catheter
ablation techniques. If symptomatic ventricular tachyar-
rhythmias are not controllable by all available means they
may lead to the need for ventricular assist or the insertion of
a total artificial heart (58). Ventricular assist has been used
successfully to provide hemodynamic support and allow
effective pharmacologic arrhythmia suppression as a bridge
to transplantation for refractory arrhythmias (59–62). Al-
though LV support has frequently been adequate for bridg-
ing patients with refractory tachyarrhythmias to transplan-
tation, permanent support may be better provided by total
support devices.
5. Cardiac allograft dysfunction and/or cardiac allograft
vasculopathy. The intermediate-term survival of patients
with severe allograft CAD is very poor. Keogh and col-
leagues reported the mortality of patients with severe CAD
in a study of 353 heart transplant recipients from Stanford
University with a mean follow-up post transplant of 5.5
years (63). In this study, the mean survival for patients dying
from CAD was 15 months from the detection of any
coronary disease (range 1 to 74 months). Survival was
statistically worse in patients with .70% stenosis in a
primary epicardial coronary artery. Survival at two years was
13%. Actuarial survival after the diagnosis of .70% stenosis
in three primary epicardial vessels in this population was
,50% at one year, half of these patients dying within the
first six months. In a recent study from the Cardiac
Transplant Research Database, CAD was defined as “se-
vere” if the left main coronary artery or two or more primary
vessels had stenoses of .70% or if there were isolated
branch vessel stenoses .70% in all three coronary artery
systems (64). In 46 patients with severe CAD, actuarial
freedom from death due to CAD (n 5 17) or re-
transplantation for CAD (n 5 6) was only approximately
36% by two years after the diagnosis of coronary disease.
Although the use of intracoronary stents may alter the
natural history of patients who develop more proximal
lesions amenable to this mode of therapy (65), the majority
of patients who develop CAD will have progressive disease
with a similar rate of progression irrespective of when the
disease is initially diagnosed (66).
Although re-transplantation is offered to patients with
severe disease at some institutions, this practice is discour-
aged elsewhere in recognition of the limited supply of donor
hearts and the lower survival after repeated transplantation
(39). Therefore, the population of patients with severe
allograft CAD is one that may be considered for studies of
biventricular support and the use of the total artificial heart.
Current estimates suggest that there may currently be about
2,000 such patients. Table 4 outlines the potential advan-
tages and disadvantages of this population as recipients for
long-term destination therapy of mechanical circulatory
support devices.
B. Evaluation for Exclusion Criteria
Patients who are acutely ill, including those without prior
known cardiovascular disease suffering an acute MI with
CS, will often develop some degree of non-cardiac end-
organ and systemic dysfunction. Indices of organ dysfunc-
tion place the patient into a risk group in which support
devices are warranted but in which they also increase the
likelihood of post-operative complications. Although cur-
rent experiences are not large enough for extensive multi-
variable analysis of risk factors for death and complications
after mechanical support, experience with current implant-
able VADs has revealed some predictors of poor outcome
during or post-device implantation (53,67).
In almost every major registry of VAD follow-up (68,69)
and a single center review (70), poor renal function or renal
failure has been a significant predictor of death following
LVAD implantation. Although renal insufficiency has cus-
tomarily been defined by an elevated serum creatinine,
oliguria in the face of adequate filling pressures may be more
predictive in acute decompensation because the creatinine
may not increase quickly, especially in a cachectic patient. In
the combined Columbia Presbyterian Hospital and Cleve-
land Clinic experience, oliguria, defined as urine output
,30 cc/h despite maximal medical therapy with diuretics,
was the most important predictor of perioperative death,
with a risk ratio of 3.9 (67). In this analysis, the second most
important predictor was respiratory failure, defined as the
need for intubation, with a relative risk of 3.0. The presence
of a coagulopathy, defined as the inability to correct the
prothrombin time to ,16 s indicated significant liver
dysfunction and carried a risk ratio of 2.4. Other pre-
operative risk factors identified in this study included a
central venous pressure $16 mm Hg (relative risk 3.1), the
LVAD placement as reoperation (relative risk 1.8) and a
leukocyte count .15,000/mm3 (relative risk 1.1).
If the placement of an LV support system alone (without
an RV support system) is being considered, the condition of
the RV should be assessed. In addition to the possibility of
Table 4. Cardiac Allograft Recipients with Severe Allograft
CAD: Potential Advantages and Disadvantages of Destination
Mechanical Support
A. Advantages
1. Very poor short-term prognosis
2. Followed (usually) by heart failure physicians and surgeons
3. Accustomed to participation in protocols and a structured medical
follow-up program
4. Limited options for therapy if not candidate for re-transplantation
5. More qualified to give informed consent after careful consideration
6. Surgical therapy may be scheduled semi-electively
B. Disadvantage of proposed population
1. Immunosuppression (usually relatively low long after
transplantation, may be discontinued after total artificial heart
other than steroids, which should be weaned)
2. Must be carefully screened for co-morbid medical problems that
would affect short- and intermediate-term survival
3. Effect of residual allograft tissue unknown
CAD 5 coronary artery disease.
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an elevated pulmonary arterial pressure secondary to HF
(71), the reactive pulmonary hypertension associated with
cardiopulmonary bypass and thromboxane A2 release may
predispose to significant RV failure early post-isolated
LVAD placement. Also, the LVAD may suddenly mark-
edly improve RV filling, leading to worsening RV failure. In
one series, although the need for perioperative RV support
was low, a low preoperative pulmonary arterial pressure
(indicating decreased RV function) and a low RV stroke
work index were significant risk factors for RVAD use (72).
Others have shown that strong predictors of subsequent RV
dysfunction after LVAD implantation were the pre-implant
medical condition, presence of end-organ failure, pulmo-
nary edema and coagulation abnormalities (73). Factors to
be considered in all patients are prior surgical history, prior
radiation therapy, the general medical and nutritional con-
dition of the patient and the patient’s social support struc-
ture (74).
C. Selection of Devices
Studies of new mechanical support devices should be tar-
geted toward specific populations with high anticipated
mortality with conventional therapy but a reasonable chance
of surviving device placement and the perioperative period.
Two broad categories of potential device recipients can be
identified: 1) those with acute, potentially reversible condi-
tions, and 2) those with chronic generally irreversible
disease. In the first category, ideally devices should be
inexpensive and easily inserted and removed. The second
category of patients would benefit from devices with greater
longevity, even if the device is more difficult to insert and is
more expensive. Patients with intractable malignant ar-
rhythmias and severe transplant vasculopathy will require
the capability of biventricular support. Heart transplant
candidates requiring mechanical bridging remain an excel-
lent population in which to assess the feasibility of new
potential long-term devices. Table 5 outlines the relative
importance of various device characteristics as applied to
potential recipient populations.
D. End Points for Outcomes
It is clear that appropriate end points to be incorporated into
future clinical trial designs for mechanical circulatory sup-
port devices will need to vary according to the nature of the
patient population to be included in each trial and the
particular device being subjected to trial. For instance,
simple all-cause mortality at six months might be an
appropriate end point in a group of patients selected who
had a .50% probability of death within six months,
whereas more complex measures of “quality-adjusted sur-
vival” would be appropriate in a less sick population. All
trials should be designed to incorporate measures of cost,
cost-effectiveness and tracking of device malfunction and
device failure. Quality of life will become an increasingly
important end point to assess and should be compared with
valid control groups of patients rather than relying on the
patients’ own perceptions of their quality of life before and
after placement of the device. It should be recognized that
quality of life is a subjective and individual assessment and
that the currently available tools to measure quality of life
are imperfect and have not been well validated in advanced
heart failure. It may be necessary to revise and validate tools
for this specific patient population.
The following sections outline some generic suggestions
for appropriate primary and secondary end points for patient
groups of differing severity of illness. Each end point may
have time-related “midpoints” to be assessed as well.
1. The end points for critical populations. Survival over
the next three to six months is a major challenge for patients
who are New York Heart Association (NYHA) functional
class IV and compromised enough to depend on ongoing
intravenous inotropic support to maintain secondary organ
function and overall circulatory sufficiency. When trials of
mechanical systems commence in these patient populations,
Table 5. Relative Importance of VAD Characteristics by Potential Patient Population
Patient Population
Chronicity of
Underlying
Situation
Ease of
Insertion
Ease of
Removal
Device
Longevity
Biventricular
Capability
Appropriate for
Long-Term
Outcome Study
Relative
Low Cost
I. CS
CHF with exacerbation into
critical low output state
Chronic 111 1 111 11 111 11
Acute MI Acute 111 111 1 11 1 11
Post-cardiotomy shock Acute 111 111 1 11 1 111
II. CHF, dependent on
intravenous inotropic
therapy
Chronic 1 1 111 1 111 11
III. CHF, class IV symptoms on
oral therapy
Chronic 1 1 111 1 111 11
IV. Uncontrolled malignant
arrhythmias
Acute/chronic 111 11 11 111 111 11
V. Chronic severe post-transplant
graft dysfunction with
allograft vasculopathy
Chronic 1 1 111 111 111 11
CHF 5 chronic heart failure; CS 5 cardiogenic shock; MI 5 myocardial infarction; VAD 5 ventricular assist device; 111 indicates greatest importance.
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it is suggested that end points of such trials include the
components listed in Table 6.
2. Ambulatory heart failure on oral therapy. Patients
with NYHA functional class IV symptoms who are
candidates for chronic mechanical circulatory support and
who are not recurrently hospitalized or dependent on
intravenous inotropic agents are generally not “as sick” as
patients dependent on intravenous inotropic support.
These patients can experience discomfort during any
physical activity and may have discomfort while at rest.
The hypothesis is that a mechanical circulatory support
device will provide such patients with an improved
physiologic and functional quality of life and for a
duration that extends well beyond the 30-day post-
implant period. As discussed above, the probability of
survival at a specific time is not well established.
The primary end point for clinical studies of devices
intended for use in these patients would be all-cause
mortality at a specified duration, such as six months, one or
two years, although mortality due specifically to cardiac
events should also be captured. End points of quality of life
may assume more importance for these patients, for whom
a sustained improvement in quality of life may be considered
a significant benefit even if survival is equivalent (76).
Quality of life is a multidimensional construct measuring
outcomes in the following domains: emotional state, general
health perception, pain, social function and physical func-
tioning. There is considerable debate about appropriate
measurements for quality of life, but experience in assessing
these aspects is rapidly being gained (77,78).
These domains can be analyzed and integrated in the
context of patient preferences for health-related quality of
life versus length of life. These measurements seek to
capture the overall value or preference that a patient holds
for a particular health outcome. Both the time trade-off
instrument and the standard gamble questionnaire have
been used to determine the relative value placed by an
individual patient on the degree of perceived health versus
remaining survival time or risk of death while pursuing
better health (42,76,79). They may have greater relevance to
decision-making than abstract scores. Preference ratings can
serve as the quality adjustment factors for calculating quality
adjusted survival, measured in quality adjusted life years
(QALY). Such measures are expressed as numeric values on
a uniform scale (0 to 1). They are particularly useful for
summarizing overall changes in health-related quality of life
because they are expressed as a single score.
Morbidity parameters as listed in Table 6 should be
secondary end points, but they will assume increasing
significance and may become primary end points in trials of
less sick patients for whom, if survival is equivalent and is
associated with significantly less morbidity, significant ben-
efit may be considered to have been demonstrated. The
frequency of each event and the time to each event should be
captured for reporting in the application for approval for
marketing by the FDA. In addition, device (system) mal-
functions and device (system) failures are adverse events that
should be captured for purposes of facilitating design
improvements. The location where each morbidity event
occurs and where each device malfunction and device failure
occurs should be documented to establish device (system)
safety in its intended user environment (in-hospital vs.
out-of-hospital).
Because the relationship between cost and benefit is a
significant issue in the evaluation of these devices, all cost
information associated with this therapy should be collected
for comparison with costs incurred by patients who do not
receive a device. This includes costs associated with hospi-
talizations, caregivers in and out of the home, travel and
medications. Cost-effectiveness is an analytical technique
that looks at the rate paid to obtain a measure of health.
This is often expressed in dollars per life year saved. When
quality of life is taken into consideration, this is expressed as
dollar cost per QALY saved. This form of analysis provides
the optimal means to allocate health care resources to
maximize the health benefits achieved.
Some might argue that certain therapies that are shown
to have a defined benefit would prove to be too expensive for
society to bear. On the other hand, we recognize that in
some cases society has been willing to expend significant
resources for a limited benefit to the population as a whole.
It is conceivable that, although the actual cost may be
extremely expensive for mechanical circulatory support, this
Table 6. End Points (Assessed at Prespecified Time Intervals)
Primary end point: All-cause mortality
Secondary end points:
A. Quality of life
B. Functional capacity, for example:
Exercise capacity (if applicable)
Hemodynamics
Ability to leave hospital
C. Cost
Device cost—system and replacement parts
In-hospital costs
Out-of-hospital costs (to include medical, caregiver-related and,
possibly, travel-related costs)
Cost-effectiveness*
D. Components of morbidity (75), including:
Thromboembolism
Neurologic events
Infection
Bleeding
End-organ dysfunction
Right heart failure
Psychiatric episode
Rehospitalization (if discharged)
Cardiac causes:
Worsening heart failure
MI
Arrhythmia
Non-cardiac reasons
E. Device malfunction (to be specified in detail)
F. Device failure (to be specified in detail)
* Cost-effectiveness—complex analysis based on parameters of quality of life, required
care, survival, and cost, see text.
MI 5 myocardial infarction.
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therapy may significantly improve quality of life and return
large numbers of individuals to a productive role in society
and thus ultimately be considered cost-effective. Analysis of
cost-effectiveness during the current stage of device devel-
opment may not adequately reflect the eventual value or
beneficial impact of mechanical circulatory support thera-
pies, but such assessment can be expected to become more
favorable as experience with devices, quality of devices and
scope of their use expand in the future.
IV. ESTABLISHING EFFICACY FOR DEVICES:
ETHICAL AND PRACTICAL CHALLENGES
A. Therapies for Life-threatening Illness
The life-saving potential, procedural risks and costs associ-
ated with mechanical circulatory support for patients with
end-stage heart failure mandate the thoughtful development
of a basis of evidence for efficacy, safety and cost-
effectiveness. The Medical Device Amendments of the
Food, Drug, and Cosmetic Act require that new devices be
“safe and effective” before they can be marketed and that this
evidence be provided through “well-controlled scientific
studies” or through “valid scientific evidence” (80). Mechan-
ical assist devices fall into the highest of three risk categories
defined by the Amendments; class III being life supporting
or sustaining and having substantial importance in prevent-
ing impairment of health or having a potential to incur risk
of injury or illness. For these devices, the sponsor must
conduct clinical trials before the FDA grants marketing
approval through a so-called PMA decision. Incremental
changes to already marketed devices may be approved
through a supplemental PMA. Selection of the research
design for evaluating a specific mechanical circulatory sup-
port device must reflect: 1) the nature of the medical device
innovation, 2) the severity of illness of the patients, and 3)
the timing within the regulatory approval process (i.e., pre-
and post-marketing observations).
The devices under imminent consideration are designed
for patients with advanced stages of heart disease. Duration
of observation is more limited when severity of illness is
higher, as in current populations with acute or chronic
refractory class IV heart failure. Knowledge of the grim
natural history at this stage increases allowance for consid-
eration of therapies available outside of the device investi-
gational protocol. In other areas of life-threatening illnesses,
such as cancer and AIDS, limitations in life expectancy have
led to attempts to look at alternative research designs for
approving new regimens of care, which would minimize the
ethical conflicts of offering only one “active” treatment arm
(81). Under these conditions, efforts have also focused on
trying to shorten the pre-marketing clinical trial and FDA
review processes, lessening the level of evidence necessary
for safety and efficacy PMA, while shifting more emphasis
to rigorous post-marketing studies.
B. Differences Between Development of Drugs
and Devices
By comparison to pharmaceutical innovation, device inno-
vation is more incremental and iterative in nature, as has
been the case for LVADs. Both before and after approval
for clinical indications, these devices have undergone con-
tinuous modification of drivelines, electronic controllers,
alarms, connectors, vents, conduits and power supply sys-
tems. In the initial stage, this process merits a determination
of the initial feasibility without a control arm for devices not
previously tested in humans. For drugs, this has often been
a dose-ranging study with non-mortality end points such as
hemodynamics or exercise capacity. Further benefits of the
initial testing phase for any therapy include the defining of
promising study end points and the estimation of the sample
size required to show a clinically significant benefit. Perhaps
even more so for devices than for drugs, premature entry
into a clinical trial phase invites the risk of failure or, at least,
the need for redesign and retesting.
The relationship between cause and effect is generally
more transparent for devices than for drug therapies. Both
good and bad results of device implantation are often
evident within hours or days, compared with longer and
more modest effects over years during the recent drug trials
in mild-to-moderate heart failure. It is less likely that the
benefit or harm of devices can be masked or mimicked by
the natural history of heart failure. The attribution of
outcomes may thus be somewhat less prone to bias for
devices than for drugs.
The transparent effects of devices also inform both
patient and physician with regard to treatment arm in a
randomized trial. Even if it were acceptable to perform
sham surgery, the physical characteristics of the device
would challenge provision of a placebo. This is a major
difference between trials of devices and trials of drugs, in
which patients on a placebo often assume that they are
receiving active and “best” therapy. In addition, treatment is
in general difficult or impossible to withdraw for recipients
of support devices, by contrast with the trivial nature of
withdrawal from a drug study. The cost of developing,
manufacturing and ensuring quality of devices is vastly
higher for devices than for drugs. Many innovative devices
are developed in small companies without previous product
revenue to support clinical trials. The total cost per patient
is more than an order of magnitude higher than for drugs.
The higher costs are balanced in part by the higher expected
magnitude of benefit, such that calculated sample sizes are
proportionately lower than for drug trials. The expertise and
experience required for successful device implantation re-
strict the eligible sites in trials of devices. These restrictions
also limit the generalizability of results after approval, when
use extends to centers with less expertise.
The sum of evidence guiding therapy for drugs is domi-
nated by evidence from the large trials completed prior to
drug approval. Once approved, it is difficult to identify use
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and attribute effects of any particular drug because of the
variability of prescription and adherence in complex regi-
mens of other medications. For this reason, post-marketing
surveillance provides limited information regarding drugs
for heart failure except for non-cardiovascular side effects.
By contrast, the very complexity and undisguised impact of
devices render their use and outcomes easier to track, as long
as appropriate registries are maintained. The cumulative
body of evidence guiding the ultimate use of devices may in
the final analysis be weighted more heavily by information
gained after initial approval.
C. The Potential for “Breakthrough” Devices
It is possible that initial studies in the future could identify
a therapy with such obvious impact that it would be
considered a “breakthrough” for a population with otherwise
high early mortality. In this case it would be neither
necessary nor ethical to perform a prospective trial with a
control group in this population. Freedman acknowledges:
“In the rare case when the first evidence of a novel therapy’s
superiority would be entirely convincing to the clinical
community, equipoise is already disturbed” (82). As was
pointed out by Norman Shumway, the pioneer of cardiac
transplantation, no randomized trial of cardiac transplanta-
tion has even been conducted, and it is likely that none will
ever be. In retrospect, cardiac transplantation was thus a
breakthrough. Early mortality was high, but transplantation
was considered to represent a major advance over the
presumed imminent mortality of the initial recipients.
Current mechanical support devices as bridge to transplan-
tation were in fact recognized as effective for this purpose
and accepted with only contemporary cohort data. In part,
because of the differences described in the preceding text,
such a breakthrough in the near future appears more likely
for a device for heart failure than for a drug.
Most new therapies do not achieve breakthrough status
during preliminary testing but fall somewhere along the
spectrum before approval (Fig. 1). Short of an unequivocal
breakthrough, there may be some therapies that are not yet
approved but are nonetheless considered by experienced
clinicians to be sufficiently effective that an RCT is not
acceptable. When this is recognized, clinical equipoise is
absent, and a randomized clinical trial cannot ethically be
performed. The best way to bridge this gap and expedite
regulatory approval of effective therapies has not yet been
determined for any of the life-threatening diseases.
It is important to recognize that no new technology is
likely to represent a breakthrough for every population
considered. Even for a device promising 80% six-month
survival for patients with end-stage heart failure, the design
of trials would remain relevant when extending the tech-
nology to those populations with lesser severity of illness in
whom the benefit of the device could not be assumed.
D. Ethical Considerations Governing
Trials of Mechanical Circulatory Support
1. Requirement for clinical equipoise. The ethical basis of
randomized clinical trials in general has been debated
(83,84). On one hand, a physician has a responsibility to an
individual patient to provide the best care possible, and a
randomized treatment would not allow the clinician to
provide the perceived best care. On the other hand, it has
been argued that without robust, clinical evidence from
well-designed trials, physicians cannot decide what is best
care, and indeed, physicians’ perceptions of optimal treat-
ment have at times been shown to be wrong (84). When the
question is one that is appropriately addressed by a random-
ized clinical trial, a fundamental task for investigators is to
understand the ethical and scientific principles.
The ethical conduct for clinical trials of a new therapy
rests on a fundamental tenet: the therapy has the promise of
some benefit, but its efficacy to achieve this benefit is
unknown and the new therapy always carries some risk.
Clinical trial ethics demand genuine uncertainty over
whether the treatment arm is superior or inferior to the
control arm. Equipoise, the principle of uncertainty regard-
ing the merits of two or more treatments (82), is required of
the investigators to conduct ethical research. If an investi-
gator believes that one treatment has been proven to be
superior to another, then the ethical basis for the RCT is
lost and the investigator may not ethically randomize his or
her patient to the inferior treatment. However, investigators
generally have some bias about which treatment is “best,”
which has led to considerable debate about what is truly
required for an investigator to maintain equipoise. “Theo-
retical equipoise” has been described as an odd and ethically
irrelevant state that could exist only when the clinical data
supporting two treatments is essentially equal. Theoretical
equipoise is fragile; it is easily disturbed by new data, and it
may be inappropriately sensitive to the investigator’s per-
ceptions of trial outcomes. A more insightful understanding
of equipoise, Freedman proposes, is that of “clinical equi-
poise,” in which genuine debate and uncertainty exist in the
clinical community regarding a new treatment or interven-
tion. Evidence must be present to support both sides, and
for new treatments with little or no preliminary data,
opinion must exist both for and against such a new
treatment. Clinical equipoise accommodates even decided
treatment preferences by individual clinician investigators
during the conduct of a clinical trial if widely spread debate
exists between clinicians, and clinical equipoise remains
until convincing evidence has been formally presented,
reviewed and widely accepted by the medical community at
large (82). The clinical equipoise paradigm has been ex-
tended recently by the suggestion that the physician inves-
tigator, as part of the subject recruitment, divulge his or her
treatment preference (85). It is possible that this may cause
greater numbers of patients to take the “best medical advice”
from their physicians, with the result that fewer patients
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may enroll in trials, particularly of therapies available else-
where. However, this potential conflict may be mitigated by
a careful and complete presentation of the scientific merit
for the trial, including evidence both for and against the
investigational treatment, which forms the ethical basis for
the study design and conduct.
It is not ethical to do a trial that is unlikely to provide
adequate information. The research protocol must be prop-
erly designed to test the new approach. Because of the
potential for harm, the question being addressed must be
one that is medically important. There needs to be proper
matching of the active and control interventions to the
patient group being studied. The trial must also be feasible,
with adequate resources available to properly conduct and
complete the trial. The trial must be able to measure the end
points chosen and generate useful data. Finally, it must
actively monitor for known and unknown adverse effects,
and it must be approved by an institutional review board
whose major mandate is to protect the rights and safeguard
the welfare of human research subjects. The approved
protocol must be thoroughly presented to a subject and
accompanied by a written consent form. In the most com-
monly used design, the subject then decides whether or not to
participate in the clinical trial and, if he or she agrees to
participate, provides voluntary consent and is randomized.
2. Ethical issues in patient selection for mechanical
circulatory support. Which aspects of RCTs for circula-
tory support devices merit special ethical consideration?
Because these devices are currently designed to intervene for
life-threatening heart failure, one ethical challenge is the
question of whether any imminently terminally ill patients
should be entered into RCTs. It has been suggested in the
oncology literature that such recruitment for otherwise
unavailable therapy may have aspects of coercion (83).
Several points, however, emerge in support of enrollment.
First, some patients seek clinical trial participation. They
may receive purpose and device satisfaction from participa-
tion in a research protocol prior to death. They may provide
themselves with more comprehensive care. Their participa-
tion may ensure that they will not be abandoned, and their
interaction with clinical trial staff may yield greater comfort.
Second, and more specific to trials of end-stage heart failure,
defining the “imminently terminally ill” condition for pa-
tients is extremely difficult if not impossible, as described in
the preceding text. For clinical trials of surgically implanted
devices, it may be unwise to recruit and randomize a truly
moribund patient, because the higher operative risks may
obviate any clinical benefit and may jeopardize the clinical
trial end points. If the recruitment of such a patient flirts
with medical futility, it may also be ethically questionable
because it may jeopardize meaningful end points contrib-
uted by other subjects. As the severity of both natural illness
and operative risk shift down, as described above, the more
appropriate operative candidates for device therapy also have
a greater likelihood that enhanced medical therapy, perhaps
including outpatient inotropic therapy, may provide months
of survival with some reasonable quality of life outside of the
hospital (86). The difficulty in making accurate predictions
of life expectancy for presumed end-stage heart failure, in
combination with the unknown risk/benefit outcome with
mechanical circulatory support, provide the most persuasive
foundation for clinical equipoise regarding randomized
clinical trials of current circulatory support devices.
Allocation of mechanical circulatory support also raises a
question of whether it is ethical to restrict a novel but
unproven technology to a certain group of people. Left
ventricular assist devices have been approved by the FDA
only for use as bridging devices for heart transplant recipi-
ents. The current randomized clinical LVAD trial restricts
the study population to those with advanced heart failure
who require but do not qualify for cardiac transplantation
(13). The ethics of this issue have been extensively reviewed
(87). Clinical trials demand that subjects be selected so that
some benefit from an LVAD intervention can be demon-
strated, thereby benefiting the trial and other patients in the
trial. Left ventricular assist device therapy has been seen as
inferior to cardiac transplantation; therefore, potential car-
diac transplant patients may reasonably be excluded from a
destination therapy trial because investigators are not ethi-
cally mandated to offer an inferior treatment (87).
3. Ethical issues surrounding randomization. When an
appropriate candidate has been identified, randomization in
a trial of mechanical circulatory support poses unique
challenges if subjects may be randomized to receive a device
or conventional therapy consisting primarily of drug treat-
ment. Such fundamentally different treatment approaches—
one surgical and the other medical—have been associated
with substantial subject and investigator treatment bias and
ambivalence about random treatment assignments. This
bias is of special significance for a fatal disease, as previously
noted for cancer patients (81). Patients may passionately
favor the new device technology, or they may shrink from a
mechanical approach that requires a life-threatening oper-
ative intervention. Such fears are magnified by the nature of
device surgery, which makes “treatment withdrawal” diffi-
cult, unlikely and inadvisable, by contrast with pharmaceu-
tical trials. Technical considerations that prevent blinding of
either investigator or patient to treatment selection remove
an otherwise powerful antidote to investigator and subject
bias. Such concerns have created considerable difficulty in
recruiting patients for the first randomized LVAD clinical
trial. Finally, for physician investigators, attaining and
maintaining clinical equipoise throughout a randomized
clinical trial between dramatically different treatment op-
tions may be inherently problematic.
A major conflict arises for clinician investigators who
then perceive an obligation to provide device treatment, if in
light of the new and extensive information provided as part
of the consent process, the patient has concluded that the
device therapy may be life-saving and is clearly in his or her
interest for survival. The investigator must rightfully ac-
knowledge that the dilemma of a patient’s requesting one
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arm of a randomized trial would be less likely to arise if
comprehensive information had not been provided during
recruitment efforts. Increasingly, however, patients arrive
with a preconceived notion of their imminent mortality and
a favorable impression of the device therapy that has been
disseminated through the media prior to patient recruit-
ment. Anecdotal reports indicate that this situation has
occurred—and understandably so, considering the nature of
the designated population, which suffers the chronic low
cardiac output syndrome and faces death over days, weeks or
months. The patient with far-advanced disease may perceive
that a successful device implant, although not guaranteed,
may provide some reasonable chance to survive with im-
proved quality of life. Does the scientific community, as
investigators, linger at equipoise longer than they would as
these patients?
What is an appropriate response from the investigator to
a potential study subject who requests the device therapy
arm rather than randomization? One generic response
might be that the presentation by the investigator may not
have been appropriately balanced. Although this generic
comment is highly relevant to most clinical trial protocols,
certain patients and circumstances may make this outcome
unavoidable for mechanical cardiac assist device trials. It
may in fact not be possible to adequately transmit informa-
tion from which patients could provide a truly informed
consent to a complex trial with outcomes that are outside
any of their known experiences. Should a patient be per-
mitted to choose the device therapy arm?
Similar issues have been raised in drug development for
AIDS (83). Alternative trial designs to include patient
preferences (88) have been proposed. Such trials might
conceivably lessen conflicts with patient preferences and
perhaps enhance recruitment, with greater generalizability
of outcomes (89), as described in the following text. It has
been argued that most patients in clinical trials are likely to
have preferences anyway, which may influence outcomes
(90). However, such trials may increase cost and compro-
mise scientific integrity of the data (88). Ethically, it does
not appear mandatory that a patient be offered the perceived
superior “treatment arm” preference as long as clinical
equipoise is present.
4. Ethical issues after randomization. For patients who
do proceed with trial participation to randomization, anec-
dotal reports of patients randomized to the control arm
without device suggest some may be despondent and feel
that they have been “sentenced to death.” Such responses
give rise to two concerns. First, it is possible that a patient’s
preference for the treatment not received may influence his
or her own quality and length of life and bias the outcome
of a device trial, which preferentially enrolls patients who
prefer active treatment. That patient preferences may have
an important impact on the outcomes of randomized
clinical trials has been postulated, but little data exist in this
area (91). Depression has been well-documented to lead to
worse outcomes with chronic illness. Expert clinicians know
well that a significant loss and the consequent despondency
can precipitate decompensation in an otherwise stable HF
patient; it is conceivable that such an emotional blow as to
miss a randomization to a perceived life-saving device might
be life-threatening in itself. If patient despair occurs in
significant numbers, the resultant drop out or loss-to-
follow-up and patient defection to receive investigational
therapies elsewhere could prevent meaningful comparison of
the treatment arms. Such experiences challenge the other-
wise persuasive Freedman position of “clinical equipoise.”
There may be both ethical and practical rationale for
considering some controlled circumstances in which devices
could be provided for “compassionate use” during the course
of a trial (see “Design of Clinical Trials for Mechanical
Circulatory Support” below).
5. Future ethical issues for equipoise. To date, the Freed-
man concept of clinical equipoise has been appropriate and
attainable for an RCT for mechanical circulatory support,
granted that reasonable and serious debate has existed about
which treatment may be superior and comprehensive lon-
gitudinal clinical data have not been available in non-
transplant patients. With the anticipated rapid progress of
mechanical circulatory support development and additional
clinical trials, considerable effort will be required to main-
tain clinical equipoise. Although clinical equipoise provides
a powerful basis for assessing the ethical conduct of pro-
posed controlled clinical trials, the mechanisms by which
clinical equipoise moves ahead to reach a new ethical basis
is poorly defined for specific issues, perhaps particularly so
for rapidly evolving device innovations. Our current society
receives broad but shallow information, with immediate
reports of clinical trial results and patient testimonials on the
front pages of national newspapers. Both professionals and
the public are challenged to discern knowledge from infor-
mation and to know what is right for now; that is, to decide
the basis for clinical equipoise. As we assess new generations
of mechanical support devices, how will our present ethical
basis be challenged, and for what reason and by whom will
our ethical basis be shifted? Will it be led by governmental
agencies, industry, investors, clinical investigators and pa-
tients reading news reports, or by other groups? Perhaps an
objective, expert multidisciplinary group would be helpful in
identifying and resolving the ethical dimensions of clinical
trials of assist devices.
E. Design of Clinical Trials for
Mechanical Circulatory Support
Over time, a wide variety of methods (clinical trials, quasi-
experimental techniques, decision analysis, economic anal-
ysis and meta-analysis) have evolved to assess outcomes of
new therapies. Those that involve primary data collection
can be differentiated by whether or not reliable techniques
were used at the data acquisition stage to control for
variables that can limit the identification of cause and effect
relationships between the intervention and outcome of
benefit or harm.
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1. Randomized clinical trials. The prospective random-
ized clinical trial is the consummate clinical experiment
designed to minimize ambiguity in the interpretation of
study results by striving for equality between comparison
groups at the time of their assembly. It is widely regarded as
the most powerful and sensitive tool for comparing thera-
peutic interventions (85). As discussed above, this experi-
ence has derived largely from trials of drugs for mild-to-
moderate HF. Despite the theoretical strengths of the
method, and its pivotal importance in trials of pharmaceu-
tical agents in HF, there are daunting challenges in applying
randomized clinical trials to the evaluation of potentially
life-saving devices for end-stage heart failure. Many of these
challenges arise from the differences between drugs and
devices as detailed above, particularly with regard to the
ethical issues arising from the inability to blind the patient
or physician to the treatment arm. The unique nature of
these challenges was discussed in detail in the preceding
section. It should be emphasized, however, that knowledge
of the treatment assignment has immediate practical impli-
cations also because the patient’s preferences for a device or
for no device may compromise both enrollment in, and
adherence to, the treatment assignment. In one of the
original trials of therapy for AIDS, blood tests were positive
for the investigational therapy in 9% of the patients in the
placebo arm, indicating off-protocol drug acquisition (92).
Interpretation of outcomes is also influenced by knowl-
edge of the treatment arm. Sham operations are very
controversial (91,92) and would not be compatible with the
palpable and audible function of current mechanical devices.
Expectations by patients and physicians may influence the
recognition of complications, the intensity of other thera-
pies and perhaps even survival. Important study end points
also include the subjective assessment of symptoms and
quality of life. Even exercise performance, ostensibly more
objective, is influenced by the expectations of patients and
physicians.
Measuring survival in trials that compare devices to
medical therapies presents methodological concerns differ-
ent from those presented when comparing similar therapies.
When device therapy involves a high up-front operative
risk, with a subsequently reduced mortality compared with
controls, the survival curves are likely to cross. Analyzing the
differences between such curves depends on the analytical
method chosen and the time frame of the analysis. Most
analyses such as the log-rank and Wilcoxon methods
average risk over the follow-up period. Extending or reduc-
ing the follow-up time then has the potential to reverse the
order of relative efficacy, because more or less weight will be
given to the respective mortality in the perioperative period.
Moreover, crossing survival curves imply lack of a consistent
proportional relationship in the relative mortality of the two
treatments. This violates the basic assumption in using
proportional hazard methods, which have been the standard
for survival analysis procedures.
Special needs in cancer and AIDS research have affected
a number of advances in clinical trial methodology by
employing statistical methods that permit not only more
rapid and sensitive evaluation of toxicity but also adjust-
ments in design based on the interim outcome experience
within a trial (81). Further successful community-based
strategies, particularly in the testing of anti-AIDS interven-
tions, have overcome problems with patient recruitment,
treatment and development of appropriate informed con-
sent. Understanding of the special challenges involved in
evaluating mechanical support will be necessary in the
development of novel trial designs that lower obstacles while
preserving the advantages offered by the randomized clinical
trial.
Financial impediments have affected the conduct of VAD
clinical trials profoundly. The issue of funding is central
because device companies are often innovative organizations
with limited cash reserves and few sources of income.
Shrinking budgets for academic centers limit their resources
in the face of the increased time required to prepare
documents for institutional review boards, screen patients
and provide detailed data for studies with limited enroll-
ment. Moreover, the unreimbursed costs of the surgical
procedure and recovery are substantial. Cutbacks in health
care reimbursement prevent hospitals from continuing to
support such visible programs internally as “loss leaders.”
These disincentives to patient enrollment ultimately in-
crease the overall duration and cost of the study.
The decision by the executive branch of the federal
government to begin reimbursing the routine treatment
costs of Medicare patients enrolled in clinical trials is an
important step in the right direction. Beyond payment for
routine costs, the concept of conditional coverage is increas-
ingly advocated, in which insurers (such as Health Care
Financing Administration [HCFA]) support the costs of
patient treatment associated with both arms of a well-
designed clinical trial, while the sponsors (e.g., National
Institutes of Health or Industry) cover the costs of conduct-
ing the research. There is strong support from this confer-
ence for such conditional coverage.
2. The REMATCH trial. Despite the above limitations,
an RCT to determine the impact of a mechanical circulatory
support device on outcomes with end-stage heart failure is
nearing completion. The ongoing REMATCH trial com-
pares the ThermoCardio System implantable LVAD as
“destination therapy” with optimal medical therapy in pa-
tients who are not candidates for transplantation (13), using
the criteria defined above. Initiation and enrollment into
this study have been delayed for both centers and patients by
many of the issues described. Sufficient patients have been
randomized, however, to reach meaningful conclusions. If a
survival benefit is proven for this device in this population,
future control groups for destination therapy may be receiv-
ing this device or receiving continued medical therapy if
they have established contraindications to its placement.
Even if no statistically significant benefit is demonstrated in
the mechanical device-supported patients, the information
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obtained from both standard therapy and the assist device
arms will influence device testing and population selection
for future clinical device trials.
3. Modifications of the randomized controlled trial for
mechanical circulatory support devices
a. OPTION OF LATER “COMPASSIONATE” USE OF DEVICE. It
should be re-emphasized that the gold standard methodol-
ogy for deriving firm information regarding the impact of
the treatment on outcomes remains the randomized,
double-blinded, placebo-controlled trial, with hard, well-
defined primary end points of major clinical importance
(23). It should also be recognized, however, that surgical
interventions in patients with advanced illness may not
appropriately lend themselves to all aspects of this method-
ologic gold standard, such as blinding to treatment. In
designing trials for such interventions, one should begin by
seeking to implement the ideal design and to deviate from
the ideal only as is practically necessary. It is essential to take
into account the impact of trial design modifications on the
resulting data before drawing conclusions regarding the
treatment effect.
Future design of a trial in which a circulatory device is
compared with medical therapy might include a later offer of
“compassionate cross-over” for interested patients. This
would technically not be a “cross-over” trial because patients
with HF would not routinely have the option to cross back
from device to medical therapy and the patients receiving a
device after randomization to the control arm would not be
analyzed with the original device cohort. Provision of the
device could be offered after a predetermined time period
during which early survival and intermediate-term func-
tional data would be obtained. Alternatively or additionally,
the demonstration of certain pre-established criteria of
disease progression could be considered as a surrogate end
point, after which the device would be offered compassion-
ately, recognizing that the operative risk might be higher at
this time than at the time of randomization. The option of
receiving a device in the future would offer hope to patients
disappointed by initial assignment to no device. In addition
to reducing some of the ethical concerns, this provision
might actually render a more valid comparison of the two
arms, by realigning the incentives for both physicians and
patients to persevere through the control period without the
device. It would hopefully decrease the risk of losing
patients to follow-up as they seek this therapy in a less
supervised setting elsewhere. For many of the reasons
discussed above, these increased options would be expected
to enhance enrollment and adherence to follow-up. This
potential increase in enrollment needs to be balanced with
the increase in sample size required to determine clinically
significant differences.
b. POTENTIAL INFLUENCE OF INITIAL PATIENT PREFER-
ENCE. The ability of a patient to select a particular modality
of therapy in a clinical trial may not only significantly
enhance enrollment but also potentially influence the out-
comes after treatment (88–90). This argues for examining
the preferences of patients as a factor that might influence
the end point of the trial. One way of accomplishing this is
to measure patient preferences for treatment assignment
immediately before randomization and, if they are related to
the primary end point, to use the results to adjust the
primary comparison. A partially randomized design would
give patients the option to either become part of a tradi-
tional randomized trial or take the therapy of their choosing.
In a trial of two interventions, this results in four arms. The
comparison of the two randomized arms offers the infor-
mation of a standard RCT. Absolute confirmation regard-
ing device outcome and complications is available for the
patients choosing the device therapy, although there is no
parallel control group. Comparisons between the random-
ized and nonrandomized arms, which must be treated as
observational study, would give some indication of the effect
of patient preferences on outcome.
4. Comparison of non-randomized cohorts. Alternative
designs may be considered when the RCT is not considered
appropriate, such as for established devices that incorporate
limited improvements. It is also conceivable that cohort
studies may be found acceptable when initial evidence of
efficacy has persuaded the clinical community away from
equipoise but has not yet led to formal device approval (Fig.
1). Cohort studies have employed both historical and
prospective controls. With RCTs at the top of the hierarchy
of research design, there are various levels of descending
rigor for observational reports, all of which are susceptible to
considerable bias. Controlling for selection bias can be
improved by: 1) restriction of inclusion criteria to define
relatively homogeneous cohorts with some loss of general-
izability; 2) matching, such that each patient in one cohort
is paired with one or more patients with a similar baseline
profile for a limited number of key prognostic factors, which
need to be better defined for advanced HF; 3) stratifying—
comparing rates within subgroups with clinical characteris-
tics that put them at the same risk of the outcome event,
which can be done only for a few characteristics before
statistical power is lost; and/or 4) adjusting for difference in
clinical characteristics between the cohorts, using regression
techniques. Unfortunately, none of these can control com-
pletely for the factors that led to the provision of a therapy
to one patient and not to another, if the therapy was
potentially available for both. An interesting example is the
comparison of patients who received implantable LVADs as
bridges to cardiac transplantation and those in the same
centers who did not, for reasons attributed to device
availability. This indicated a major benefit from devices used
as bridges to transplantation, for which they were subse-
quently approved. However, generalization of the results to
non-transplant candidates predicted a substantial benefit
that was not borne out in the randomized pilot trial (52).
Meta-analyses of observational trials have in some cases
predicted the results of well-designed randomized trials
(93,94) but in other cases have been contradicted and
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supplanted by such trials (95). It has been suggested that
“when recruitment of patients for an RCT is exceptionally
difficult, threatening to make the sample of patients unrep-
resentative, neither reliance on RCTs nor reliance on
observational studies is wholly satisfactory” (95,96).
a. HISTORICAL CONTROLS. There is a paucity of large
“clinically rich” datasets in patients with class III and class
IV heart failure. There is also little data on the components
of medical therapy for truly class IV CHF patients. The
Flolan International Randomized Survival Trial (FIRST)
(97), examining the use of the vasodilator epoprostenol, and
the recent Outcomes of a Prospective Trial of Intravenous
Milrinone for Exacerbations of Chronic Heart Failure
(OPTIME CHF) trial (98), examining the use of milrinone
during HF hospitalization, demonstrated high mortality
regardless of medical treatment. The Pre-Transplant Re-
search Database (51) demonstrated high mortality in pa-
tients hospitalized or on intravenous inotropic agents, with
mortality of only 13% for other patients awaiting transplan-
tation (a younger population with fewer co-morbidities than
patients currently considered for implantable devices).
When concluded, the REMATCH trial will provide unique
information on approximately 70 such patients receiving
optimal medical therapy, and for a brief period, it will
represent the most current data available. Historical controls
provide useful information that requires interpretation in
the context of the original reasons for data collection.
Medical therapy is in a dynamic state, so reference to
databases previously obtained may provide general guidance
but is unlikely to sufficiently validate a new therapy unless it
is in the breakthrough realm.
b. PROSPECTIVE CONTROLS. Some of the problems of his-
torical controls can be addressed by assembling the control
cohort prospectively, along with the “experimental” cohort
group. Once patients have qualified for participation in the
study, their assignment to a particular cohort will depend on
the goals of the study. Patient assignment, however, must be
made in light of the need to establish cohorts that are equally
constituted with respect to the risk for the primary measure of
outcome. Despite the use of restriction, matching and strati-
fication, cohorts are rarely evenly matched, and comparisons
between the cohorts require analytical adjustment to account
for differences in baseline patient characteristics.
i. Timed graduation from control cohort to active therapy.
One approach is to enroll patients formally for a fixed time
period before the device is implanted. This provides a brief
period during which early mortality for the population can
be determined. There is reason to suspect, however, that the
patients dying during this interval were at initially higher
risk than those surviving the observation interval preceding
implantation. Alternatively, the period of delay may lead to
clinical deterioration that increases the operative risk to a
higher level than it was at the time of enrollment. Several
factors thus render the initial cohort different from the
group later undergoing device implantation.
ii. Patient preference cohort studies. A patient preference
study (a prospective cohort study allowing patients to
choose which therapy they want) may be of considerable
appeal to patients (see preceding text). Those patients
selecting their preferred treatment rather than randomiza-
tion would constitute the preference cohorts. Depending on
the planned comparisons, patients might also be given the
option to cross over to the newer therapy after specific early
end points if their opinions change and the change is
technically feasible. This type of trial might greatly enhance
recruitment because eligible patients with end-stage HF
who fear a device may be more willing to allow themselves
to be followed in the medical treatment arm. Such patients
are currently not likely to be enrolled in any device trials.
Similarly, many patients who would be reluctant to enroll in
a trial because they might have only a 50% chance of being
assigned to a device would now enroll. The fundamental
drawback to this design is the possibility that self-selection
of a particular therapy is, in some way, associated with the
primary measure of outcome, making the groups unequal at
baseline. This has not been determined.
iii. Risk-based allocation cohort studies. One approach that
is being investigated for breast cancer therapy is to allocate
therapy in clinical trials based on risk assessment, such that
those patients deemed at greater risk of dying from the
underlying disease would receive the experimental therapy
and those at less risk would receive standard therapy (99).
The treatment effect is measured by comparing the observed
results of the experimental group with a projection of the
effect of standard treatment on the experimental group,
based on a mathematical model. The model would be
derived from observations made on the control group.
Although this type of trial design is only now being
examined, it may provide a novel method for studying the
use of VADs in patients with complex heart failure. For
investigating therapies of advanced HF, this trial design
would be hindered by the limitations of our ability to
identify risk profiles and predict outcomes in advanced HF.
F. The Vital Importance of Registries
1. Outcomes database for advanced heart failure. The
growing national burden of advanced heart failure argues for
the establishment of an ongoing registry at a number of
institutions that would include information regarding ther-
apies and outcomes. The large heart failure databases that
have generated new mechanistic hypotheses have been of
mild-to-moderate heart failure rather than the more severe
heart failure responsible for most of the morbidity and
mortality associated with this diagnosis. The complexity of
this condition, with multiple etiologies, co-morbidities,
therapies and modes of death, poses greater challenges to
risk profiling and modelling than those encountered with
specific cancers or AIDS. Despite the prevalence of ad-
vanced HF, however, there have been no national resources
devoted to collaborative efforts to assemble such data.
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There are several scientific and societal reasons for a
greater commitment to this population. A registry of ad-
vanced heart failure would accelerate progress in developing
mechanical circulatory support and other new therapies.
Greater confidence in our ability to identify high-risk
populations would accelerate the recognition of devices in
the breakthrough realm. Indications for specific populations
could be more readily defined. By virtue of its larger size, a
registry offers a better opportunity for matching character-
istics of an experimental group with a cohort of controls
selected from the dataset. Moreover, a registry would
support the development of a regression model that can be
used to adjust for differences in assembled cohorts, multi-
variate regression modeling being the major technique
employed for diminishing bias in cohort comparisons. The
design of RCTs would be streamlined by better selection of
target populations and prediction of event rates.
2. Registries for implantable devices. There is now broad
consensus that there should be a mandatory registry for all
implantable mechanical circulatory support devices. The
impact and implications of device approval and acceptance
are much greater than for those of any pharmacologic
component of the medical regimen. The number of devices
and patients that form the basis of approval is of necessity
relatively small, and extensive further experience is required
to optimize the clinical utility of new devices. The current
consensus is that further development of implanted circu-
latory devices without plans for such a registry is unethical.
The same factors of technical complexity—cost outlays
for the device and consoles, requirements for site expertise
and the transparent impact of devices—that hinder large
randomized trials prior to device approval may in fact
facilitate ongoing surveillance after device release. In recent
years, there has been increased attention to the potential of
post-marketing studies to accelerate the process of approval.
By contrast with pharmaceutical therapies, which are easier
to study before approval and harder to supervise afterward,
mechanical circulatory support devices may be supported by
a weight of evidence distributed differently between pre-
and post-approval experiences.
Past experience with all manufacturers has, however,
demonstrated the numerous limitations of a voluntary reg-
istry, including a lack of uniform criteria for device inser-
tion, variable surgical experience, incomplete data submis-
sion at all time points, cost issues and proprietary/marketing
issues. There is nonetheless strong precedence for maintain-
ing registries for implanted valves and pacing devices.
Device manufacturers as well as health care providers must
report information indicating that a device may have caused
or contributed to a death or serious injury. In the case of
high-risk devices, companies must keep records of patients
with implanted devices. It should be possible to require
specific baseline data collection on patients with mechanical
assist devices after device approval if that stipulation is
formally linked to the initial approval of the device.
In addition to patient survival data, regulatory agencies
are likely to require post-approval clinical studies to expand
on specific components of the safety profile for devices, such
as infections or thromboembolic events and documented
device failures and replacement. It is not known to what
extent a mandatory registry can require specific detailed
data, but a registry would provide a useful common denom-
inator as a template. While post-marketing studies have
generally used observational methods, the concomitant de-
velopment of improved registries both for devices and
advanced HF should allow more sophisticated modeling to
determine relative outcomes of devices versus medical strat-
egies. If there are numerous post-marketing studies that
address the same issue, meta-analyses can be used to
statistically combine the results of these individual studies to
a degree justified by the similarity of devices. This form of
analysis can help to resolve uncertainty when studies dis-
agree as well as to answer questions that were not posed at
the start of the individual studies. Moreover, it can improve
estimates of the magnitude of therapeutic benefits and risks.
Compared with trials of drugs and drug classes, meta-
analysis has perhaps been underutilized for the analysis of
the effects of mechanical assist devices.
It is unclear how the responsibility of supporting such
registries should be allocated between industry and govern-
mental agencies. The greater challenge is presented by the
larger and more diffuse population with advanced HF, for
whom there is no industry incentive to support systematic
recording of outcomes. There are currently a number of
proposals in the process of submission to direct and main-
tain a registry of implantable devices.
V. FUTURE DEVICES
ENTERING CLINICAL DEVELOPMENT
A. Existing Minimum Standards for
Pre-Clinical Device Evaluation
There is presently no standard for the pre-clinical evaluation
of devices used in mechanical circulatory support systems.
The FDA Office of Device Evaluation still provides useful
information and interaction for blood pump developers, but
officially, there is no existing standard for the pre-clinical
evaluation of these devices. Consequently, it is recom-
mended that circulatory support system developers schedule
a pre-investigational device exemption (IDE) submission
meeting with the FDA to educate the reviewers in advance
on the specifics of their system and to receive feedback from
the FDA on the appropriate criteria for the review of their
system. Two guidelines for pre-clinical device evaluation do
exist. First, the Preliminary Draft Guidance for Ventricular
Assist Devices and Total Artificial Hearts issued by the
FDA in December 1987 is the original document. Although
it is useful in presenting criteria for device evaluation, it is
considered obsolete. It also needs to be recognized that the
document was issued early in the clinical experience of using
VADs and total artificial hearts for bridging to transplan-
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tation. The full extent of the circumstances in which these
devices would be used (i.e., in and out of the hospital and for
durations of months to over a year) could not be fully
anticipated by that document. Hence, the periodic revision
of the criteria for evaluation became both necessary and
appropriate for the evaluation process and a source of
frustration for device developers and investigators.
The second guideline comes from a joint paper developed
by an ASAIO and the STS interdisciplinary working group
(including participants from academia, industry, the NIH
and the FDA). This working group jointly published a
reliability recommendation for long-term blood pump sys-
tems in 1998 (100). This recommendation has been used to
guide the reliability evaluations for blood pump systems that
are currently under development or that have recently
entered clinical trials. It needs to be emphasized, however,
that this recommendation is limited to reliability concerns
for long-term devices, so there is still a need for a more
comprehensive standard with specific criteria for pre-clinical
in vitro and in vivo testing and evaluation of devices.
As long-term clinical experience has been gained with
circulatory support systems in bridge-to-transplant, bridge-
to-recovery and alternative-to-transplant settings, it has
become clear that the performance goals for these systems
needs to be revised from values stated in or related to the
FDA Preliminary Draft Guidance. Controversy has existed
over the required duration of pre-clinical animal implanta-
tion tests and reliability mission life duration. Concern has
been expressed over the recommended duration of pre-
clinical reliability mission life duration (some consider the
recommended minimum of one year to be too short for a
long-term system) and the duration of the animal implan-
tation trials (some consider the recommended 90 days to be
too long), but there is insufficient evidence to address these
concerns at this time. It also needs to be recognized that
although the longer use of these circulatory support systems
is the primary motivation for updating minimum criteria for
pre-clinical device evaluation, the pre-clinical criteria for
devices intended for short-term use (i.e., post-cardiotomy
CS and transient right heart failure after LV assist implan-
tation) and bridge-to-recovery also need to be examined and
accommodated in a new standard. The revision of these
guidelines becomes even more crucial as the definitions for
short- and long-term devices become less clear based on
clinical applicability. Previously, patients undergoing post-
cardiotomy support were felt to require periods of support
not extending beyond 10 days to 2 weeks. There are now
anecdotal reports showing that recovery has, in fact, been
seen with periods of support extending several weeks to
several months. In addition, there is the distinct possibility
that the patient may become device-dependent, changing
what was originally anticipated to be a short-term support
period to an extended period as either destination therapy or
a bridge to cardiac transplantation. Another perspective to
consider is that devices need to be specifically designed to
meet the needs of the identified patient population.
The FDA Preliminary Draft Guidance Document and
the ASAIO/STS Reliability Recommendation are still con-
sidered to be useful documents by several blood pump
development groups. However, the need for a current and
comprehensive standard for pre-clinical evaluation of de-
vices remains. To begin to address this need, the Associa-
tion for the Advancement of Medical Instrumentation
(AAMI)1 is presently leading the interdisciplinary develop-
ment (including participation by the FDA2 of a Technical
Information Report (TIR). The AAMI TIR is in the final
development stages. It is expected to be available from the
AAMI by the end of the summer of 2000. It must be
recognized that due to the uniqueness of each blood pump
system, this document provides a comprehensive review of
blood pump system issues to be evaluated and considered for
inclusion in a FDA IDE submission, but it does not provide
a checklist of specific performance requirements. However,
the AAMI document does provide several references to
guidelines and standards on specific topics related to blood
pump systems. Ultimately, the comprehensive design, im-
plementation and documentation of a blood pump system
development program with validated in vitro and in vivo
testing using sound scientific protocols for data collection
and analysis will lead to a successful FDA device review.
Finally, some criteria need to be developed to clearly
identify system standards for devices that can be used in
different situations for variable clinical indications as the
definitions of bridge-to-transplantation, bridge-to-recovery
and destination therapy become less distinct. It is not
uncommon for example, for a device to be implanted for a
post-cardiotomy indication, and then removed much later
(three to six months) than intended, because the recovery
process may be longer than anticipated. In addition, at some
point if the patient cannot be weaned, he or she can be
converted to a transplant candidate. On the other hand, if
adverse events occur that preclude transplantation, the
device may have to perform in the mode of destination
therapy. Thus, reliability requirements, which may have
been sufficient for post-cardiotomy use, are now ill-defined
for permanent use.
The development of a comprehensive standard for the
pre-clinical evaluation of blood pump systems, though
needed, is not presently being planned. The effort to create
such a standard would require a rigorous interdisciplinary
effort over a period of three to five years. Until such a
standard is developed, it is incumbent upon the members of
the blood pump development community and the FDA
Device Evaluation staff to share the lessons they have
learned to advance the understanding of the pre-clinical
blood pump evaluation process. It is also incumbent upon
the FDA Device Evaluation staff to continue their difficult
1 AAMI, 3330 Washington Boulevard, Suite 400, Arlington, VA 22201-4598,
Tel: (703) 525-4890.
2 U.S. FDA, Center for Devices and Radiological Health, Office of Device
Evaluation, Division of Cardiovascular and Respiratory Devices, 9200 Corporate
Boulevard, Rockville, MD 20878, Tel: (301) 443-8262.
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job of fairly and expeditiously submitting reviews, while
being cognizant of the need to revise their criteria as the
clinical experience with circulatory support systems grows.
Because of the uniqueness of each blood pump system and
its intended use, the development of a fixed true standard
may be an unachievable goal. A more farsighted approach
may be a continuing, interdisciplinary revision of a guidance
document for blood pumping systems.
B. Devices Currently in Clinical Development
The first section of this conference document reviewed the
devices currently available in the U.S. for intermediate or
long-term support. This section reviews the mechanical
circulatory support systems that are likely to enter clinical
trials as chronic support devices in the U.S. within the next
five years. Such devices fall into four major categories: 1)
continuous flow LVADs (including axial flow and centrif-
ugal flow pumps), 2) pulsatile LVADs, 3) the total artificial
heart and 4) devices without blood contact.
In general, these new devices first undergo extensive
ex-vivo reliability testing followed by chronic animal im-
plantations. The third phase is human trials, which gener-
ally begin with a single site and then expand to five to
twenty centers, testing the device initially as either a bridge
to transplantation or as a chronic implant. Clinical trials are
then performed to obtain PMA.
1. Continuous flow left ventricular assist devices. Con-
tinuous flow, or rotary devices, are currently of two basic
types: axial flow pumps and centrifugal flow pumps. They
have several potential advantages over current pulsatile
pumps: 1) they are smaller devices and therefore can be used
in smaller patients (less than the 1.5 m2 body surface area
(BSA) required for most pulsatile devices); 2) they are
relatively simple, have fewer moving parts than pulsatile
pumps and thus may be less prone to mechanical failures,
although this is unproven; 3) because of the continuous flow
characteristics, they do not require a compliance chamber in
the system; 4) they have lower energy requirements; and 5)
the small size of the device and the pocket may decrease the
risk of infection, although this is also unproven. These
devices also have potential disadvantages that remain to be
quantified: 1) current axial flow pumps use bearings lubri-
cated by blood, and this area of relative stasis is a potential
source of in-situ thrombus or thromboemboli; 2) chronic
anti-coagulation is necessary; 3) some degree of hemolysis is
common, the long-term effects of which are unknown; 4)
the long-term effects of non-pulsatile (or essentially non-
pulsatile) flow are unknown; and 5) feedback control mech-
anisms for pump speed are complex and unproven.
a. AXIAL FLOW PUMPS. Three axial flow pumps are likely to
undergo “first generation” chronic device trials in the U.S.,
with several trials underway in Europe. They include the
Nimbus/TCI IVAS, the Jarvik 2000 IVAS and the De-
Bakey/MicroMed IVAS. The axial flow motor is small and
contains rotary blades that spin at 10,000 to 20,000 rpm and
can pump approximately five to six l/min. Because of the
continuous flow properties of the axial flow pumps, there are
no valves in the system.
The Nimbus IVAS (HeartMate II) is a small (7 cm
length) axial flow pump that connects to the LV apex for
inflow and the ascending aorta for outflow (101). Under
normal operation, the inlet pressure to the axial flow pump
will be cyclical, varying with the systolic-diastolic phases of
the LV, creating some degree of pulsatility. An electromag-
netic motor (pump rotor) turns the turbine. A low-pulse
mode produced by variable motor speed will also be avail-
able. Two cup-socket ruby bearings support the pump rotor.
The outer boundary of the bearing’s adjacent static and
moving surfaces is washed directly by blood flow. The
pump’s speed can be controlled manually and by a proposed
auto-mode that relies on an algorithm based on pump
speed, inherent native cardiac pulsatility and current. A first
version of this device is powered through a percutaneous
small-diameter electrical cable connected to the system’s
external electrical controller. A fully implantable system is
under development.
The Jarvik 2000 Heart is a similar, compact (5.5 cm
length, 85 gm weight) axial flow pump that receives inflow
from the LV apex and outflow through a Dacron graft
anastomosed to the descending thoracic aorta (102). The
rotor constitutes the only moving part of the device and is
supported at each end by tiny blood-immersed ceramic
bearings (103). The currently existing device is tethered to
an external electrical power source through a percutaneous
wire, but a subsequent totally implantable version will
contain a microprocessor-based controller that can sense
and change pump speed according to different phases of the
cardiac cycle and receive power via a transcutaneous energy
transfer system coil.
The MicroMed DeBakey Axial Flow Pump is an elec-
tromagnetically actuated, implantable titanium axial flow
pump that connects to the LV apex and ascending aorta.
The pump is designed to produce flows of 5 l/min against
100 mm Hg pressure with a rotor speed of 10,000 rpm
(104). The currently existing design of this pump includes a
fixed rpm rate that can be adjusted through an external
device. During periods of patient mobilizations, power can
be supplied by two 12-volt DC batteries for several hours.
b. CENTRIFUGAL FLOW PUMPS. Centrifugal flow devices are
somewhat larger than axial flow pumps and provide non-
pulsatile flow, but the rotational speeds are much slower
(about 2,000–4,000 vs. 10,000–20,000 rpm). The same
general advantages and disadvantages apply to centrifugal
flow pumps as to axial flow pumps.
The AB-180 Circulatory Support System is a small,
durable implantable centrifugal pump that receives inflow
from the left atrium and empties into the ascending aorta
(105,106). The rotor is powered by electromagnetic cou-
pling. A solution of distilled water and heparin provides a
high local concentration of anticoagulant within the pump.
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An occluder device prevents retrograde flow from the aorta
to the left atrium in the event of pump failure. Although it
is potentially useful for long-term support, the AB-180 CSS
will first be tested as a support device for post-cardiotomy
shock.
The HeartMate III LVAD is a centrifugal pump pow-
ered by magnetic levitation, a process that combines the
functions of levitation and rotation in a single magnetic
structure. The small pump rotor does not contain bearings
and is completely encased in titanium.
The CorAidey centrifugal blood pump is an implantable
LVAD with a suspended rotor that is noncontacting. The
pump produces 8 liters/min flow at 6.5 W.
2. Pulsatile flow devices. Excluding the Novocor and TCI
HeartMate (discussed under “Current State of Devices”),
pulsatile LVADs likely to enter long-term clinical trials
within the next five years are the Thoratec Intracorporeal
Ventricular Assist Device (IVAD), the Novacor II, the
Worldheart HeartSaver VAD and the Arrow Lionheart
VAD. Each of these chronic LVADs requires chronic
anti-coagulation with coumadin.
The Thoratec IVAD is designed as a small lightweight
device for left or biventricular support (107,108). This
IVAD maintains the same blood flow path, valves and
polyurethane blood pump sac as the paracorporeal Thoratec
device. The major advantage of this IVAD is its relatively
small size (339 gm) and simplicity in a pulsatile system that
can be implanted in patients ranging in weight from 40 to
$100 kg. Only the small blood pump is implanted in a
pre-peritoneal position with a small (9 mm) percutaneous
pneumatic drive line for each VAD connected to a more
complex control unit externally, where it can be serviced and
replaced. The pump is controlled with a small briefcase-
sized, battery powered pneumatic control unit.
The Novacor II miniaturized pulsatile pump is an exten-
sion of the current Novacor technology that substantially
reduces pump size. The single pump is replaced by two
small sac-type pumps, each driven by a central pusher plate
mechanism, supporting the LV output through multiple
pump cycles. The pusher plate is driven by direct electro-
magnetic actuation, resulting in a simple bearingless system.
The Worldheart HeartSaver VAD was designed as a
totally implantable chronic VAD and has several major
attributes: 1) the device is totally implantable and requires
no percutaneous connections; 2) it is designed for implan-
tation in the left hemothorax adjacent to the natural heart
and can be anchored to the rib cage; 3) the device is
remotely monitored and controlled; 4) an internally im-
planted and rechargeable battery allows the patient to
partake in a variety of activities, unencumbered by any
external components; and 5) the device can be implanted
without cardiopulmonary bypass. The blood contact surface
of the sac is fabricated from polyurethane and the valves are
porcine tissue valves. An electromagnetic coupling device
transfers power across the intact skin and tissue. Wireless
monitoring and control of the device is provided by a
transcutaneous infrared biotelemetry system.
The Arrow LionHeart VAD is another totally implant-
able LVAD system with tilting disc valves in which trans-
cutaneous energy is transferred to implanted batteries (109).
The energy converter is based on a roller screw mechanism,
which in turn causes linear motion at a circular pusher plate
that compresses the polyurethane blood sac during systole.
In diastole the motor reverses to withdraw the pusher plate.
An intrathoracic compliance chamber maintains near-
thoracic pressures in the energy converter airspace. External
electronics consist of the energy transmission source, a
power pack, a battery charger and portable power supplies.
3. Total artificial hearts. Two total artificial heart systems
are expected to enter clinical trials in the U.S. within the
next five years. They include the Abiomed Total Artificial
Heart and the Penn State Total Artificial Heart. Both
pumps require chronic anticoagulation with warfarin 6
anti-platelet agents.
The Abiomed Total Artificial Heart (AbioCor) is a
completely implantable system that can generate cardiac
output in excess of 10 liters/m. Powered by transcutaneous
energy via coils, an internal battery is included for 20 to
40 min of tether-free time. All blood-contacting surfaces,
including the two blood pumps and four tri-leaflet valves,
are fabricated from seamless polyurethane (angioflex).
Blood flow is maintained by a high-efficiency miniature
centrifugal pump, which operates unidirectionally, while a
cylindrical rotary valve alternates the direction of the hy-
draulic fluid flow between the left and right pumping
chambers. Left/right balance is achieved by adjusting the
right prosthetic ventricle stroke volume via a hydraulic shunt
mechanism that incorporates a balancing chamber attached
to the left prosthetic ventricle inflow port (110).
The Penn State/3M Total Artificial Heart is a totally
implantable device based on a rotor screw mechanism that
produces 8 liters/min with a stroke of 64 ml (111). Circular
pusher plates are attached to the two ends of the rotor screw
shaft, and a brushless DC electric motor rotates the screw
6.3 revolutions to provide a full pusher plate stroke with
1.9 cm linear motion. One pump empties while the other
fills, and the motor then reverses to eject the opposite pump.
A seamless polyurethane blood sac fits within each titanium
pump case, and Bjork-Shiley convexo-concave or Delrin
monostrut valves (2.5 mm inlet, 27 outlet) provide unidi-
rectional flow. Left/right balance is achieved by the use of
estimated end-diastolic volume from motor speed and
voltage. A compliance chamber is coupled to the housing to
accommodate volume changes caused by gas diffusion from
the blood and changes in atmospheric pressure. Energy is
passed through a transcutaneous system to an implanted
controller box and Nilco rechargeable battery (45 min
tether-free). There is a subcutaneous port for access to the
compliance chamber.
4. Devices without blood contact. Currently existing de-
vices without blood contact are designed for short-term
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support. However, the development of similar devices for
chronic therapy appears likely. The Abiomed Heart Booster
combines an LV volume constraining device with a con-
tractile component. Control of LV dilatation is effected by
a conical “jacket” that fits over the apex of the heart. The
contractile component is based on a change in the shape of
multiple thin-walled tubes from a circular cross-section to a
highly elliptical or flat cross-section, and vice versa. Rapid
hydraulic inflation of the tubes (toward a circular shape)
results in a smaller enclosed volume, and rapid deflation of
the tubes (toward highly elliptical shape) results in a larger
enclosed volume. When negative pressure is applied to the
tubes during diastole, the tubes collapse completely in such
a way that the pericardial wrap becomes a thin structure that
is relatively pliable and does not impede diastolic filling.
The device wraps around the apex of the heart and, like
other volume constraining devices, does not require cardio-
pulmonary bypass for implantation. A smooth outer surface
is used to prevent tissue ingrowth around the outer surfaces
of the device and reduce diastolic dysfunction.
C. Conclusions
Results and lessons learned from trials such as the RE-
MATCH trial will inevitably influence future trial design in
the field of mechanical circulatory support. As the field
moves ahead, it has become clear that no one trial design
will be ideal or appropriate for all devices, populations and
stages of development. A variety of research designs will be
necessary. Creation of a national outcomes database for
advanced HF will facilitate effective trial design and identify
populations that may potentially benefit.
Responsible progress in this field requires the establish-
ment and maintenance of a mandatory registry that includes
all implantable devices, both before and after approval. The
combined effort of the various stakeholders is required to
address issues of funding, data format and management,
compliance and access, while balancing proprietary con-
cerns. A major achievement of this conference is the
recognition that the field will advance further and more
rapidly if the various groups involved in developing and
testing new devices can collaborate effectively in the future.
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